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The lymphatic system is a network of tissues and organs which performs a plethora of 
functions in the body by removing unwanted materials and defending against infections. 
Cancer of the lymphatic system occurs when the white blood cells, which are supposed 
to protect the body against foreign pathogens, become diseased and damaged. The 
loss of equilibrium between the regulators of cell proliferation, apoptosis, differentiation 
and adhesion resulted in the formation of tumors in the lymphaptic system, commonly 
known as lymphomas.  
One of the more common forms of lymphomas is Hodgkin lymphoma (HL) disease 
which is diagnosed by presence of malignant Hodgkin Reed-Sternberg (HRS) cells 
originating from B cells lineage. Despite the abundance of immune cell infiltrates in HL, 
HRS cells are able to escape immune surveillance. One possible mode of immune 
evasion employed by HRS cells is by attracting leukocytes and subsequent inactivation 
of leukocytes in the tumor stroma. However, the infiltration of leukocytes prior to 
inactivation by HRS cells is not well studied even though cell adhesion molecules 
(CAMs) have been known to play a part in adhesion of lymphocytes to HRS cells to aid 
in inactivation of the lymphocytes.  
hepaCAM, a cell adhesion molecule belonging to the immunoglobulin superfamily, 
consists of 416 amino acids which encodes a 46-kDa protein. It is made up of 3 regions, 
namely the cytoplasmic tail, transmembrane region and extracellular domain. hepaCAM 
has been known to modulate cell migration, cell adhesion and cell-matrix interactions 
(Moh et al., 2008; Moh et al., 2009). CD137, tumor necrosis factor receptor superfamily 
member 9 (TNFRS9), is usually found on CD8+ T cells, dendritic cells, follicular dendritic 
cells and natural killer cells. CD137L is mainly found on antigen presenting cells (APCs). 
It was recently discovered that CD137 expression in HRS cells inactivates T cells by 
internalisation of CD137/CD137L complexes (Ho et al., 2012). As CAMs and TNFRs 
have been known to work together in cancer progression, we aimed to investigate the 
role of hepaCAM in relation to CD137 in HRS cells. 
The expression of hepaCAM was regulated by CD137. As demonstrated by Western 
blot analysis, flow cytometry and confocal microscopy experiments, expression of 
CD137 in HRS cells increased the expression of hepaCAM, particularly on the cell 
surface. Colocalization of CD137 and hepaCAM was detected predominantly on the 
plasma membrane. Co-immunoprecipitation experiments using HRS cells revealed 
physical association between CD137 and hepaCAM. This association was abolished 
when the cytoplasmic tail was truncated in mutation analysis, indicating the importance 
of the cytoplasmic domain of hepaCAM t in interacting with CD137. Functional studies 
suggested a role of CD137 in hepaCAM-mediated cell adhesion. CD137-expressing 
HRS cells with increased expression of hepaCAM showed a stronger adhesion to 
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fibronectin. Moreover, introduction of activated peripheral blood mononuclear cells 
(PBMCs) to purified hepaCAM protein or HRS cells resulted in increased adhesion of 
PBMCs. Furthermore, hepaCAM promoted leukocyte attraction and infiltration to HRS 
tumor spheroids. Neutralization of hepaCAM by hepaCAM blocking antibodies 
abrogated the adhesion of HRS cells to fibronectin, adhesion of PBMCs to HRS cells 
and leukocyte attraction and infiltration to HRS spheroids. In conclusion, expression and 
localisation of hepaCAM has been found to be regulated by CD137. CD137 and 
hepaCAM may act in concert to attract the leukocytes to the microenvironment for 
subsequent inactivation of leukocytes by CD137/CD137L internalisation and may 
contribute to immune evasion of HRS cells. Understanding the functional interaction of 
these two proteins may provide alternative immunotherapy targets, opposed to 
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CHAPTER 1 INTRODUCTION
1.1 The human lymphatic system 
The human lymphatic system is a major part of the immune system 
and it carries out a plethora of functions essential for the protection of 
the body against infections and diseases. The lymph system is an 
extensive network of organs, lymphoid tissues, lymph nodes, lymph 
ducts, and lymph vessels that make and move lymph from tissues to 
the bloodstream (Choi I et al., 2012).  
The lymphatic system is involved in 1) Transportation of interstitial fluid 
from tissues, 2) Generation and transportation of lymphocytes to sites 
of infections and 3) Transportation of cancer cells to different sites 
known as metastasis. In general, the role of the lymphatic system can 
be categorised into a few main categories (Cueni LN et al., 2010; 
Shayan R et al., 2006; Kopfstein et al., 2006). 
1.1.1 Transportation of interstitial fluid 
The lymphatic system returns excess interstitial fluid from the tissues. 
About 90% of the fluids that leave the capillaries return to the 
capillaries. The remaining 10% leak into the tissues and form the 
interstitial fluid. Small proteins that leak into the interstitial fluid increase 
the osmotic pressure and result in accumulation of more interstitial fluid 
which may result in edema if remains unregulated. The lymph 
capillaries function to pick up the excess interstitial fluid and proteins, 
and return it to the lymphatic system to prevent edema in tissues. 
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1.1.2 Generation and transportation of lymphocytes as a defense 
mechanism 
The lymphatic system is crucial in the defense of the body against 
foreign objects and diseases. During infections or cancer growth, the 
lymphatic system will transport lymphocytes to the sites to fight the 
infections and diseases. The generation of lymphocytes, which act as 
effector cells in the immune system, are carried out in the central 
lymphoid tissues such as the bone marrow and thymus (Alitalo K et al., 
2011; Janeway CA 2001). 
1.1.3 Role in metastasis 
Due to the physical proximity to many tissues in the body and the 
extensive network of lymphatic capillaries and vessels, the lymphatic 
system and its components are targets for transportation of cancer 
cells in metastasis to secondary tumor sites (Davies M et al., 2008; 
Giaccia AJ et al., 2008; Minn AJ et al., 2011). In addition, due to the 
low pressure in the lymphatic vessels, there is little mechanical stress 
to migrating tumor cells (Kopfstein L. et al., 2006).  
1.2 Architecture of the lymphatic system 
1.2.1 Organisation of the lymphatic system 
The entire lymphatic system is broadly divided into the conducting 
system and the lymphoid tissues. The lymph capillaries, lymph vessels 
and ducts make up the conducting system. The lymphoid tissues are 
associated with the defense of the immune system against infections 
and cancer development. The main components are the primary, 
2
secondary lymphoid tissues and the numerous lymphocytes present in 
the lymphoid tissues. The primary lymphoid tissues are the bone 
marrow and thymus which are involved in the production and selection 
of lymphocytes. The secondary lymphoid tissues form the adaptive 
immune response by maintaining the mature naïve lymphocytes. 
Activation of naïve lymphocytes occurs mainly at the secondary 
lymphoid tissues, exemplified by the lymph nodes. 
The primary sites for HL disease occur in the lymph nodes (Figure 1-1). 
The lymph passes through the lymph nodes by the afferent lymph 
vessels before returning to the blood by the efferent vessels. Lymphoid 
follicles are a dense collection of lymphocytes such as T cells and B 
cells, and of monocytes and dendritic cells which will be elaborated in 
later sections. 
 Figure 1-1 Lymph node structure 
Adopted from Willard-Mack 2006 
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1.2.2 Lymphatic circulation 
Unlike the blood cirulation, the lymphatic circulation does not have the 
heart to pump it around the body. The one-directional circulation of the 
lymph passes through the lymph nodes from the interstial fluids to the 
subclavian veins at the neck.  
1.2.3 Major immune cell types in the lymphatic system  
1.2.3.1 T cells 
T cells are central players in the cell-mediated immunity in the body. 
They are produced in the bone marrow, matured in the thymus and 
activated at various lymphoid tissues by antigens presented by 
antigens presenting cells (Alberts B et al., 2002; Schwarz BA et al., 
2006). There are several subtypes of T cells such as helper T cells, 
cytotoxic T cells, memory T cells and regulatory T cells. The 
development of the different subtypes of T cells is shown in Figure 1-2. 
T helper cells assist other white blood cells such as in maturation of B 
cells into plasma cells and memory B cells, and activation of cytotoxic 
T cells and macrophages (Harrington LE et al., 2008; Nakayamada S 
et al., 2012). When they are presented with peptide antigens by MHC 
class II molecules expressed on antigen-presenting cells (APCs), they 
are activated.  
Cytotoxic T cells or CD8+ T cells are involved in removing virally 
infected cells and tumor cells. These cells recognize their targets by 
binding to antigen associated with MHC class I molecules, which are 
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present on the surface of all nucleated cells (Milstein O et al., 2011; 
Innacone Matteo et al., 2005).  
Memory T cells are antigen-specific T cells that persist for a long time 
after an infection has resolved. They quickly expand to large numbers 
of effector T cells upon re-exposure to the specific antigen and provide 
the immune system with “memory” against past infections (Wherry EJ 
et al., 2003; Willinger T et al., 2005). 
Regulatory T cells are critical for the maintenance of immunological 
tolerance. Their major role is to shut down T cell-mediated immunity 
toward the end of an immune reaction and to suppress auto-reactive T 
cells that escaped the process of negative selection in the thymus (Hori 




1.2.3.2 B cells 
B cells are involved in the humoral immunity of the adaptive immune 
system, acting as immune surveillance. The main functions of B cells 
are to make antibodies against antigens, to perform the role of antigen 
presenting cells (APCs) to T cells and to develop into memory B cells 
after activation by antigen interactions (Alberts B et al., 2002; Mauri 
Claudia et al., 2012). 
Each B cell has a unique receptor protein (referred to as the B cell 
receptor (BCR)) on its surface that will bind to one particular antigen. 
When a B cell encounters its specific antigen and receives an 
additional signal from a T helper cell, it can differentiate either onto a 
Figure 1-2 Development and maturation of subtypes of T cells 
Adopted from Basset C et al., 2010 
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plasma B cell or memory B cell (Figure 1-3). Other functions for B cells 





1.2.3.3 Monocytes and macrophages 
Monocytes are the largest leukocytes and they are produced in the 
bone marrow and differentiate into macrophages and dendritic cells. 
They are involved in phagocytosis, antigen presentation, and cytokine 
production. Monocytes can perform phagocytosis using antibodies or 
complement that coat the pathogen, as well as by binding to the 
microbe directly via pattern-recognition receptors that recognize 
Cambier J. et al., 2007 
Figure 1-3 B-cell development 
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pathogens. Monocytes are also capable of killing infected host cells via 
antibody, termed antibody-dependent cell-mediated cytotoxicity 
(ADCC). ADCC is a cell-mediated defense mechanism by effector cells 
of the immune system against target cells with antibodies bound to 
surface antigens, marking the target cells for lysis (Seidel. et al., 2013).  
1.3       Hodgkin Lymphoma 
1.3.1    Hodgkin Reed-Sternberg cells 
Hodgkin Lymphoma (HL) is a type of lymphoma that begins in the 
white blood cells in the body, otherwise known as lymphocytes.   
Hodgkin and Reed/Sternberg (HRS) cells have first been described as 
the hallmark cells in HL. They are called Hodgkin cells when they are 
mononucleated and Reed/Sternberg cells when they are 
multinucleated. They are usually derived from B cells which have 
undergone somatic hypermutation (Bräuninger et al., 1999; Kanzler et 
al., 1996; Küppers et al., 1994). These somatic hypermutations 
detected in IgV genes of HRS cells are clearly destructive which will 
normally cause immediate apoptotic death of germinal centre (GC) B 
cells (Kanzler et al., 1996). Therefore, it was concluded that HRS cells 
are derived from preapoptotic GC B cells which were rescued from 
apoptosis through transforming events. HRS cells are CD30 and CD15 
positive, usually negative for CD20 and CD45. The presence of these 
cells is necessary in the diagnosis of HL(Küppers R et al., 2012). 
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HRS cells, representing less than 1% of cellular infiltrates, are studied 
using a few established cell lines such as L428, L1236, KM-H2 AND 




1.3.2    Risk factors 
A risk factor affects a person’s chance of getting a disease, in this case, 
HL. Different forms of cancers have different risk factors. Some are 
inherent and genetically linked while others are due to lifestyles and 
habits. In HL, there are several risk factors that increase the risk of 
getting HL and they are listed as below. 
 
 
Figure 1-4 HRS cells have characteristic bi-nucleated or multinucleated 
appearances with pale cytoplasm. They are usually much larger than 
normal lymphocytes. 
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1.3.2.1 Epstein-Barr virus (EBV) 
Infectious mononucleosis caused by EBV infections resulted in a 
higher risk of patients diagnosed with HL. The risk is very small but 
there is a positive correlation between EBV infection and HL (Pallesen 
G et al., 1991; Herbst H et al., 1991; Jarrett AF et al., 1996). 
1.3.2.2 Gender and age 
The disease is more prevalent among males compared to females. The 
reason is unknown but could be linked to the differences in genetic 
makeup between males and females. Secondly, the prominent age 
groups which have a higher chance of having HL are from 15-40 
(especially in 20s) and in late adulthood, which is more than 55 years 
of age (Medeiros LJ and Greiner TC., 1995). The bi-modal age group 
for HL presents the higher risks posed to people in these age groups. 
1.3.2.3 Family history 
There is a familial genetic link for HL. First degree relatives of patients 
with HL have a higher chance of getting the disease (McDuffie HH et 
al., 2009; Chang ET et al., 2005). Similarly, the risk for monozygotic 
twins, but not dizygotic twins, is very high which indicates genetically 
determined susceptibility (Mack et al., 1995) 
1.3.2.4 HIV patients 
Risk of HL is elevated among patients infected with HIV (Biggar RJ et 
al., 2006; Grulich AE et al., 2007). This could be due to a suppressed 
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immune system in HIV patients that results in the corresponding higher 
risk. 
1.3.3       Staging  
1.3.3.1 Cotswold system 
The Cotswold staging system is used to determine the extent of a 
cancer’s spread and to determine the appropriate treatments to 
improve survival rates. It has 4 stages numbered I, II, III, IV, using 
Roman numbering system. A higher number indicates a more 
advanced stage of disease (Carbone PP et al., 1971). If HL affects an 
organ outside the lymph system but is next to an affected lymph node, 
the letter E is added to the stage. If the spleen is affected, the letter S 
is added. 
1.3.3.2 Bulky disease 
Bulky disease refers to tumors in the chest that are at least 1/3 as wide 
as the chest or more than 4 inches wide in other places. The letter X is 
added to the stage (Lister TA et al., 1989). If bulky disease is present, 
the patient will require more intense treatments. 
1.3.3.3 A vs B 
If the patient does not show any symptoms related to HL, the letter A is 
assigned to the stage. If the patient shows unexplained weight loss, 
high fever for unknown reasons or drenching night sweats, the letter B 
is added to the stage (Carbone PP et al., 1971). 
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1.3.3.4 Resistant or recurrent disease 
This is not used as part of the official staging system but used by 
doctors to better understand the nature of the disease in individual 
patients and to suggest appropriate treatments. Resistant or 
progressive refers to the ineffectiveness of the treatment against the 
disease when treated initially. The tumor may continue to grow and 
does not show signs of remission. Recurrent refers to the return of the 
disease after the initial successful treatment of HL. 
1.3.4       Tumor Immunotherapy 
1.3.4.1     Unconjugated anti-CD30 antibodies 
CD30, a member of the TNFR superfamily, was found to be expressed 
by the malignant HRS cells in HL. As CD30 shows a very strong 
expression on the malignant cells in HL and only a few activated 
lymphocytes and eosinophils physiologically express CD30 as well as 
little cross-reactivity with vital organs, it makes CD30 a suitable 
immunotherapy target for treatment (Schwab U et al., 1982; Falini B et 
al., 1992). Targetting CD30 has a wide range of effects which can 
induce either apoptosis or proliferation, which are dependent on the 
cell type and activation status (Horie R et al., 2003). In vitro and in 
xenograft mouse models, anti-CD30 and monoclonal antibodies have 
been observed to induce complement-dependent and antibody-
dependent cytotoxicity (Boll B et al., 2005; Borchmann P et al., 
2005;Cerveny et al., 2005).  
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Seattle Genetics-30 (SGN-30) and MDX-060 monoclonal antibodies 
were tested in clinical trials with well-tolerated toxicities and moderate 
activities in refractory and relapsed patients who had undergone 
conventional chemotherapies (Klimm B et al., 2005; Bartlett NL et al., 
2008; Ansell SM et al., 2007). 
1.3.4.2     Radioimmunotherapy 
HL disease has been shown to be highly sensitive to radiation. 
Therefore, combination therapies such as radioimmunotherapy 
seemed to be a promising approach to target HRS cells in HL. In 
radioimmunotherapy, antibodies targetting a tumor-specific antigen are 
radiolabeled to deliver radiation and kill the tumor cells. In addition, 
these radiolabeled antibdies are tagged with a beta or an alpha-emitter 
to kill the cells in the microenvironment which may contribute to the 
survival of the HRS cells (Klimm B et al., 2005).  
1.3.4.3     Immunotoxins 
An immunotoxin is a human-made protein that consists of a targeting 
portion linked to a toxin. Ricin A, which was linked to either an anti-
CD25- or an anti-CD30-directed antibody, recorded overall response 
rates at 15% (Engert A et al., 1997; Borschmann et al., 2005). In an 
ongoing phase I dose-escalation trial in relapsed and refractory HL 
patients, SGN-35, an anti-CD30-antibody- monomethylauristatin E 
(MMAE) conjugate was used. SGN-35 was designed to be stable in the 
blood and to release MMAE only upon internalization into CD30-
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expressing tumor cells. In 36 patients tested, the drug is generally well 
tolerated with 5 complete responses and 7 partial responses.  
1.3.4.4     Adoptive immunotherapy and bispecific antibodies 
Epstein Barr Virus (EBV) antigens have been detected in HRS cells of 
approximately 40% of the HL cases (Re D et al., 2005). In the most 
extensive study, 14 relapsed or refractory patients who had 
measurable disease or were considered at high risk for relapse were 
treated with EBV-specific T cells. In vivo expansion and anti-viral 
activity of EBV-specific T cells are reported including complete 
remissions (Bollard CM et al., 2004). As generation of EBV-specific T 
cells can be time consuming, it posed some problems to clinical 
efficiency. Bispecific monoclonal antibodies, which bind to the tumor 
cells, and to an immune effector cell, with a second binding site, were 
generated instead. In the study, the murine bispecific monoclonal 
antibody was well tolerated (Hartmann F et al., 1997).  
Besides possessing anti-angiogenic and anti-tumor cell activity, 
immunomodulatory compounds such as thaliomide and lenalidomide 
stimulate T cell proliferation and enhance NK cell function (Davies FE 






1.4       Cell Adhesion molecules and hepaCAM 
 
1.4.1    Classification of cell adhesion molecules 
 
Cell adhesion molecules (CAMs) are proteins present on cell surface 
which are involved in cell adhesion between neighbouring cells or with 
the extracellular matrix (ECM). CAMs are usually transmembrane 
receptors, consisting of 3 domains: the intracellular domain that 
interacts with the cytoskeleton, the transmembrane domain and an 
extracellular domain that interacts with neighbouring cells or the ECM 
Edelman GM., 1983; Albelda SM et al., 1990). The CAMs are generally 
classified into 6 families according to their structural and functional 
features: the immunoglobulin superfamily, cadherins, integrins, 
selectins, receptor protein tyrosine phosphatases and hyaluronate 
receptors. 
1.4.1.1 Immunoglobulin superfamily 
The immunoglobulin superfamily (IgSF) is one of the largest protein 
families and is expressed in a myriad of cell types such as endothelial 
cells, epithelial cells, neurons and leukocytes. The IgSF CAMs, which 
are calcium-independent transmembrane glycoproteins, operate by 
both homophilic and heterophilic interactions. The heterogeneous 
expression of the IgSF CAMs indicates their roles in various and 
diverse biological processes such as brain development, immune 
responses, morphogenesis, development of the vascular network and 
tissue sorting (Barclay AN et al., 2003; Bastien D. et al., 2009). 
15
In general, a typical IgSF CAM compromises of an intracellular domain 
in the cytoplasm, a transmembrane domain and an extracellular 
domain that contains a few Ig-like intrachain disulfide bonds loops with 
cysteine residues (Harpaz Y et al., 1994). In addition, the ectodomain 
of the IgSF CAMs may contain several fibronectin types III (FNIII) 
repeats. The intracellular adhesion molecule (ICAM), vascular-cell 
adhesion molecule (VCAM), neural-cell adhesion molecule (NCAM) 
and platelet-endothelial-cell adhesion molecule (PECAM) belong to the 
immunoglobulin superfamily. In this thesis, the molecule of interest, 
hepaCAM, belongs to this IgSF CAM superfamily. Generally, they are 
capable of binding to members from the IgSF CAMs superfamily as 
well as to integrins. 
1.4.1.2 Cadherins 
Cadherins are transmembrane glycoproteins that serve as regulators in 
diverse biological processes including cell survival, cell adhesion, cell 
sorting, morphogenesis, intercellular junctions, tissue integrity and 
tumorigenesis. The several subfamilies of cadherins include classical 
type I, type II cadherins that are usually linked to the cytoskeleton, 
protocadherins which are expressed in central nervous system and 
desmosomal cadherins which are linked to intermediate filaments 
(Hulpiau P et al., 2009; Angst BD et al., 2001). 
Classical type I cadherins include cadherins found in epithelial tissues 
(E-cadherin), neural tissues (N-cadherin) and vascular endothelial 
tissues (VE-cadherin). Cadherins are composed of 5 tandem repeats in 
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the extracellular domains which are crucial in mediating cell-cell 
adhesion, a transmembrane section and a cytoplasmic region that is 
connected to the cytoskeleton by adaptor proteins. They are calcium-
dependent single-pass transmembrane that regulate hemophilic cell-
cell adhesion. Cadherins are usually dependent on calcium for their 
adhesive functions and prevention against digestion by protease 
enzymes (Takeichi M, 1990; Jang YN et al., 2009). In addition, 
cadherins have been known to act as signal transducers, transducing 
extracellular signals into the cytoplasm of cells (Behrens J et al., 1999; 
Kim NG et al., 2011; Juliano RL et al., 2002).  
1.4.1.3 Integrins  
The integrins are surface receptors involved in cellular processes such 
as growth, immune response, development and signal transduction. 
Integrins usually form non-covalently bonded heterodimers made up of 
an α and a β subunit (Humphries M. J. et al., 2000; Nermut MV et al., 
1988). A wide variety of integrins are composed of different 
combinations of 17 α and 8 β subunits. The α subunit of the 
heterodimer contributes mainly to the binding specificity of integrins 
while both α and β subunits contribute to the adhesive properties of 
integrins. For the β subunits, there are a few subfamilies that contribute 
to different types of adhesion. β1 and β3 subfamilies contribute mainly 
to cell-extracellular matrix interactions while β2 subfamilies are mainly 
cell-cell adhesion molecules. Therefore, integrins are capable of 
mediating both cell-cell and cell-ECM interactions. The known partners 
of integrins in the ECM are fibronectin, laminin, collagen and summary. 
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ICAM, VCAM and E-cadherin are known to associate with integrins as 
well. 
In cells expressing integrins, they are usually constitutively expressed 
but require activation before they can bind to their ligands in cell-ECM 
or cell-cell adhesions. In addition, integrins are known to be involved in 
signal transduction, transducing signals from inside to outside of the 
cell as well as from the outside to inside of the cell. For signal 
transduction from the inside to outside of the cell, a cell stimulus is 
required to activate the integrin receptor via binding to its specific 
ligand. For signal tranduction from outside to inside of the cell, the 
signalling starts when the specific ligand binds to the integrin receptor 
and a signal is transmitted from the receptor to the cell (Goel H.L. et al., 
2005; Kim SH et al., 2011). 
Signaling pathways activated by integrin receptors regulate 
cytoskeletal organization, cell proliferation and cell survival pathway. 
As integrins do not possess a kinase domain or any enzymatic activity, 
they rely on binding of specific ECM ligands (such as fibronectin, 
laminins and various collagens). For example, focal adhesion kinase 
(FAK) is activated upon ligation with an integrin receptor and activates 
cell survival pathways via PI3K, Akt and MAPK/ERK. In order to 
increase affinities of integrins for the ligands, integrins are usually 
expressed in clusters on the cell surface at points of focal contacts to 
form effective and strong cell-ECM or cell-cell adhesions (Olberding JE 
et al., 2010; Patla I et al., 2010; Goel H.L. et al., 2005). This expression 
pattern of integrins on cell surfaces increased adhesive capabilities to 
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adhere to the ECM as well as provide a diverse range of molecules 
that can be bound to the integrins. 
1.4.1.4 Selectins 
Selectins are known to be crucial in recruitment of leukocytes. They are 
primarily expressed on platelets, leukocytes and endothelial cells, 
mainly responsible for the transient attachment and rolling of 
leukocytes along the activated endothelium before tighter adhesion to 
the endothelium followed by extravasation at sites of vascular injury 
and inflammation. Structurally, selectins consist of an extracellular 
domain composed of an amino-terminal calcium-dependent lectin 
domain which binds carbohydrate ligands, and epidermal growth factor 
(EGF)-like domain and approximately 2 to 9 repeat units similar to 
those found in complement binding proteins. There are 3 groups of 
selectins with different functions. L-selectin are receptors for specific 
adhesion of leukocytes to endothelial cells of lymph nodes; E-selectin 
are involved in mediation of inflammatory responses and are often 
found to be up-regulated after stimulation by inflammatory agents; and 
P-selectin, which are important players in clotting and platelet 
activation, are contained in storage granules of platelets. P-selectin are 
expressed on endothelial cells as well and aid in adhesion between 
leukocytes and platelets (Cotran et al., 1998; Parham P et al., 2005; 




1.4.1.5 Hyaluronate receptors 
The hyaluronate receptors are transmembrane receptors that bind to 
hyaluronate in the ECM. Interactions between hyaluronate receptors 
and hyaluronate in the ECM have been known to mediate cell-cell 
adhesion. In addition, hyaluronate receptors appear to bind to actin 
filaments of the cytoskeleton and play a part in cell movement. 
Important processes are modulated by hyaluronate receptors such as 
cell motility (Hardwick C et al., 1992; Isacke CM et al., 2002), 
angiogenesis (Slevin M. et al., 2007), wound healing (Alaish SM et al., 
1994; Chen WY, 1999) and proliferation (Alho AM et al., 1989; 
Akiyama Y et al., 2001) 
1.4.2    Types of cell adhesions 
Cell adhesions exist between cell-cell and cell-ECM to provide a stable 
network necessary for tissue architecture, tissue integrity, signal 
transduction, cell motility and cell survival. Different cell-cell adhesions 
and junctions exist, together with the attached protein complexes, to 
provide a stable connection between cells and cells, and between cells 
and the ECM.  
1.4.2.1 Cell-cell adhesions 
Cells are connected to one another through various unique and distinct 
junctions known as adherens junctions, gap junctions, desmosomes 
and tight junctions. Tight junctions and adherens junctions are linked to 
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the cytoskeleton while desmosomes are connected to intermediate 
filaments. 
1.4.2.2 Gap junctions 
Gap junctions serve as channels for communication as they form 
hydrophilic cylindrical channels to allow diffusion of ions and small 
molecules in connexons between cytoplasms of adjacent cells. Many 
cell types such as endothelial cells, epithelial cells, smooth muscles 
and cardiac cells communicate via these channels. 
1.4.2.3 Cell-matrix adhesions 
Cell-matrix adhesions are known to play crucial roles in metastasis, cell 
motility as well as signal transduction from the outside of the cell to the 
cytoplasm. These adhesions occur when activated adhesion molecules 
bind to their ligands on the ECM and link to the cytoskeleton in the 
cytoplasm (Burridge K et al., 1992; Hay ED et al., 1981; Hynes R.O. et 
al., 1990). The disturbances to cell-ECM adhesions may result in 
uncontrolled cell motility in cancer progression as well as in 
autoimmune diseases. Cell-ECM adhesions can be classified into focal 
adhesions, dystroglycan complexes and hemidesmosomes. 
1.4.2.3.1  Focal adhesions 
Focal adhesions are large protein complexes that allow the 
cytoskeleton of the cell to connect with the ECM. Focal adhesions do 
not focus on anchoring of cells to the ECM but rather, they are signal 
transducers that inform the cells of the condition of the ECM and 
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directly affect the behaviour of the cells (Riveline D. et al., 2001). In 
normal conditions, focal adhesions are relatively stable but during cell 
movements, stability is reduced as the cells need to constantly 
assemble new focal adhesions and disassemble old focal adhesions to 
increase motility. Therefore, focal adhesions play an important role in 
migrating cells and cancer metastases. In the immune system, white 
blood cells migrate along the endothelium in response to signals from 
damaged tissues to site of injuries or inflammation. Connections 
between cells and the ECM through focal adhesions often involve 
integrins. Integrins bind protein components of the ECM such as 
collagen, fibronectin, laminin and vitronectin. 
1.4.2.4 Cell migration 
Cell migration is influenced by a multitude of processes that is involved 
in a wide range of biological processes. In normal physiology, migration 
is crucial in immune surveillance, tissue formation and wound healing 
which requires precise and orchestrated cell movements to the specific 
locations. As expression of CAMs play a significant role in cell 
migration, aberrations in expression levels of CAMs are found to be 
involved in pathological situations such as tumor invasion, 
angiogenesis and metastasis.  
1.4.2.5 Cell adhesion molecules in the immune systems 
Research in recent years has shown that specific CAMs control 
inflammatory and immune responses from initial stages to end stage 
effector functions. In the immune system, migration of leukocytes to 
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tumor sites and sites of inflammation governed by CAMs play a part in 
disease progression and tumorigenesis. 
CAMs result in the adhesion of leukocytes to the endothelium and 
subsequent migration through the endothelium. These dynamic 
processes are mediated by the expression and internalization of new 
adhesion molecules at leading edges of the leukocytes, resulting in 
adhesion and de-adhesion.  
The 3 stages of leukocytes adhesion and migration are mediated by 
different CAMs interactions with their specific ligands. In the initial 
stages, the leukocytes adhere to the endothelium with rolling contacts 
involving selectin/carbohydrate ligand interactions. Subsequently, firm 
adhesion occurs between the leukocytes and endothelium before 
migration through the endothelium is carried out mainly by 
immunoglobulin superfamily such as ICAM1 on the endothelium and 
β2-integrins, LFA-1, on the leukocytes (Albelda SM et al., 1994). V-
CAM1 was demonstrated to facilitate α1β2-independent binding of T- 
and B-lymphocytes to endothelium in vitro and this molecule 
presumably facilitates lymphocyte migration through the endothelium 
(Osborn L et al.,1989).  
Secondly, adhesive interactions are known to be required for a myriad 
of leukocyte functions such as natural-killing, monocyte-mediated 
cytotoxicity, adherence of leukocytes to endothelial cells and fibroblasts, 
T cells and B cells responses (Springer TA et al., 1987; Kishimoto TK 
et al., 1989; Dustin ML et al., 1988). For example, T cells have been 
found to adhere via an LFA-1/ICAM-1-dependent mechanism to a 
23
murine cell transfected with human ICAM-1. Similar adhesive 
mechanisms have been shown to exist between cytotoxic T cells and 
its targets (Krensky AM et al., 1983). Therefore, possible interactions 
between T cells and tumors via CAMs may shed light on HL as well. 
 
1.4.3       hepaCAM 
1.4.3.1 Characteristics of hepaCAM 
hepaCAM is a cell adhesion molecule which belongs to the 
immunoglobulin superfamily. The HEPACAM gene was mapped to the 
human chromosome 11q24 and the genomic DNA sequence contains 
7 exons ranging from sizes 71-2252 bp. hepaCAM consists of 416 
amino acids which encodes a 46-kDa protein. It is made up of 3 
regions, namely the cytoplasmic tail, transmembrane region and 
extracellular domain (Figure 1-5, Figure 1-6). The cytoplasmic tail 
consists of 2 potential class III PDZ binding motifs, the transmembrane 
segment contains a prokaryotic lipoprotein lipid attachment site and the 
cytoplasmic tail is comprised of a signal peptide and 2 immunoglobulin 
domains. The overall structure of hepaCAM resembles a cell adhesion 
molecule belonging to the immunoglobulin superfamily. Although Gene 
HEPACAM encoded a protein of 46-kDa, the molecular weight of 
hepaCAM is about 75-kDa as shown by Western blot analysis. The 
difference in molecular weights is probably due to glycosylation in the 
extracellular domain and other post-translational modifications. 
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1.4.3.2 Protein structure and sequence of Gene HEPACAM 
 
Gene HEPACAM was reported to be encoding a single-pass type I 
membrane protein that localizes to the cytoplasmic side of the cell 
membrane.  
As reported on UniProt, the protein consists of 2 immunoglobulin loops, 
Ig-like C2-type and Ig-like V-type and a signaling peptide in the 
extracellular domain, a transmembrane region and a cytoplasmic tail 
segment. The immunoglobulin loops spans from residues 34-142 for 
Ig-like V-type and from residues 148-234 for Ig-like C2-type, the 
signaling peptide spans from residues 1-33, the transmembrane region 
from residues 241-261 and the cytoplasmic tail spans from residues 
262-416. 
Motif searches by PSORT II program further identified a nuclear 
localization signal peptide (residues 265-271), leuzine zipper (residue 
265-271), 4 glycosylation sites (residues 35-38; 138-141; 167-170; 
189-192) and a potential disulphide bond site (residues 168-217). In 
addition, 8 dileucine motifs (residues 22-23; 23; 24; 57-58; 107-108; 
187-188; 194-195) are found to be dispersed across the signaling 
peptide, extracellular domain and transmembrane domain of hepaCAM. 
2 other potential palmitoylation motifs were detected in the 
transmembrane domain as well (Cys260, Cys 262). Scansite analysis 
of hepaCAM revealed potential binding sites for protein kinase C 
(residue 278), Cdk5 kinase (residues 377; 384), ATM kinase (residue 



















Figure 1-5 Amino acid sequence of hepaCAM. 
The Gene HEPACAM encodes a protein consisting of 416 amino 
acids, a single-pass type I transmembrane protein belonging to the 
immunoglobulin superfamily. The residues 1-33 (orange) denote the 
signaling peptide. The residues 34-142 and 148-234 (green) denote 
the 2 immunoglobulin loops in the extracellular domain. The residues 
241-261 denote the transmembrane region. The residues 262-416 
denote the cytoplasmic tail segment. The leucine zipper is underlined 
and spans from 181-202. 4 asparagines are marked by “*”, denoting 
the potential glycosylation sites. The nuclear localization signal is 
marked by “o”. 









Sequence homology comparisons revealed similarities between 
hepaCAM and other immunoglobulin-like cell adhesion molecules such 
as CEACAM3 (Genbank Accession no: AAQ88451.1), VCAM-1 
(GenBank Accession no: NP_001069.1) and ICAM-1 (GenBank 
Accession no: NP_000192.2). The sequence homology comparisons 
exhibit a 30-50% similarity between hepaCAM and the other Ig-like cell 
adhesion molecules seen in Figure 1-7. The similarities between these 
genes are mainly in the extracellular domains containing 
immunoglobulin-like sequences such as Ig-like C2-type sequence. In 
addition, hepaCAM was reported to display structural similarities to Ig-
like cell adhesion molecules. hepaCAM possesses 2 immunoglobulin 
loops, a transmembrane section and a cytoplasmic tail which was 
characteristic of the immunoglobulin superfamily such as JAM-A JAM-
B JAM-C, CAR and ESAM (Figure 1-8). 
 
Figure 1-6 Sequence annotation map of hepaCAM 
The sequence annotation map of hepaCAM provides a clear picture 
of the different segments of a typical cell adhesion molecule 
belonging to the immunoglobulin superfamily. The potential 
glycosylation sites are present mainly in the immunoglobulin loops 
in the extracellular domain. The disulphide bond (long green line) 
and leucine zipper (grey dots) are found in the Ig-like C2-type loop. 
The nuclear localization signal is found in the cytoplasmic tail (short 

















          
 
 
Figure 1-7 Sequence homology comparisons between 
hepaCAM, VCAM-1, ICAM-1 and CEACAM3. 
Sequence homology found between hepaCAM and VCAM-1, 
ICAM-1, and CEACAM3. As most similarities occur in the 
extracellular domains where the immunoglobulin-like loops are 
present, hepaCAM belongs to the immunoglobulin superfamily of 
CAMs. 
 
Figure 1-8 Structural similarities between hepaCAM and 
members of the cell adhesion molecules immunoglobulin 
superfamily. 
Similar to JAM-A, JAM-B, JAM-C, CAR and ESAM, hepaCAM 
contains 2 immunoglobulin loops, C-type and V-type, a single-
pass transmembrane segment and a cytoplasmic tail. S-S denotes 
disulphide bonds present between cysteines in the 
immunoglobulin loops while the dots represent potential 
glycosylation sites. The length of the cytoplasmic tail is marked 
beside each figure (Ebnet K et al., 2004). 
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1.4.3.4     hepaCAM in cancer progression and metastasis  
In previous researches carried out by Dr Angela Moh and Dr Shali 
Shen, hepaCAM has found to be down-regulated in several cancers 
such as breast cancer, prostate cancer and renal cancer (Moh MC et 
al., 2005; Moh MC et al., 2008). In particular, hepaCAM was found to 
be a tumor suppressor in breast cancer as re-introduction of hepaCAM 
in breast cancer cell line MCF-7 inhibited colony formation, retarded 
cell growth and resulted in senescence-like cells which exhibited flat 
cell morphology as well as senescence-associated β-galactosidase 
activity. In addition, hepaCAM was found to induce cellular 
senescence through the p53/p21 pathway. However, the re-
expression of hepaCAM contributed to higher metastatic potential of 
the breast cancer cells which resulted in increased invasiveness. This 
was observed in breast cancer cell line (Moh MC et al., 2005). In 
prostate cancer, the re-expression of hepaCAM contributed to lower 
metastatic potential of the tumor cells (Song X et al., 2014).   
Therefore, although the expression levels and functions of hepaCAM 
may differ between different cancers, the importance of hepaCAM in 
cancer progression and metastasis can be investigated in HL.  
1.4.3.5     hepaCAM in cell growth and cell-ECM interactions 
In both HepG2 and MCF-7 cell lines, hepaCAM has been found to 
exert anti-proliferative effects, inhibits colony formation and promotes 
extracellular matrix interactions when re-expressed (Moh MC et al., 
2005; Moh MC et al., 2008; Zhang T et al., 2010). Interestingly, the 
expression of hepaCAM in both HepG2 and MCF7 cells stimulates 
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both cell-ECM adhesion and cell migration which are contradicting 
(Moh MC et al., 2005). In bladder transitional cell carcinoma, hepaCAM 
has also been found to inhibit cell proliferation through AMPK/mTOR 
pathways (Wang Q et al., 2013). 
In addition, cell motility mediated by hepaCAM has been observed to 
interact directly with the actin cytoskeleton (Moh MC et al., 2009).  As 
cell-ECM interactions are known to be directed by the actin 
cytoskeleton, we found that hepaCAM colocalized with the actin 
cytoskeleton on the plasma membrane. Co-immunoprecipitation and F-
actin cosedimentation assays revealed that hepaCAM directly bound to 
F-actin. The data suggest that an intact hepaCAM protein is critical for 
establishing a stable physical association with the actin cytoskeleton; 
and such association is important for modulating hepaCAM-mediated 
cell adhesion and motility. 
1.4.4     GlialCAM in Megalencephalic leukoencephalopathy 
1.4.4.1    Megalencephalic leukoencephalopathy 
 
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is 
a rare type of leukodystrophy (van der Knaap et al., 1995) 
characterized by macrocephaly which manifests in the first few years of 
life. It was proposed to be a potential brain channelopathy associated 
to astrocyte dysfunction (Van der Knaap et al., 2012; Lanciotti A et al., 
2013). Diffusion studies indicate increased water content of the brain 
(van der Knaap et al., 1995). Myelin and astrocyte vacuolation was 
observed in a brain biopsy from an MLC patient (van der Knaap et al., 
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1996; Duarri et al., 2011). Subcortical cysts form below the cerebral 
cortex, affecting the use of muscles and result in motor issues such as 
muscle stiffness, difficulty in coordinating movements, impaired speech, 
difficulty in swallowing and epilepsy (van der Knaap and Scheper, 2011; 
Singhal et al., 1996; Topcu et al., 1998; Bugiani et al., 2003). 
1.4.4.2   Characteristics of GlialCAM 
GlialCAM is a cell adhesion molecule with identical cDNA as hepaCAM. 
GlialCAM was found to be expressed in corpus callosum, pons, 
medulla and white matte of the cerebellum of the central nervous 
system (CNS). Other GlialCAM rich regions include small cell bodies in 
grey and white matter in the spinal cord, central canal of ependymal 
cells and glial cells such as astrocytes, oligoastrocyts and microglial 
cells (Favre-Kontula ET AL., 2008). 
1.4.4.3   MLC1 and GlialCAM in MLC 
It was proposed that MLC may be caused by impaired ion transport 
across cellular membranes which led to disturbed fluid homeostasis 
and osmotic imbalance (Brignone et al., 2011; Duarri et al., 2011). 
MLC1, discovered to underlie MLC in most patients (Leegwater P.A. et 
al., 2001), encodes an integral membrane protein with 8 putative 
transmembrane domains (Teijido et al., 2004) that is expressed mainly 
in the brain and in white blood cells (Leegwater P.A. et al., 2001; 
Teijido et al., 2004). Mutations in MLC1 accounts for 75% of all MLC 
cases (Boor et al., 2006), possibly impairing ion transport across 
membrane resulting in osmotic imbalance. Studies on MLC1 missense 
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mutations indicate that absence of cell-surface MLC1 protein 
expression is the molecular basis of MLC disease (Duarri et al., 2008). 
Changes in trafficking patterns of MLC1 to plasma membrane could be 
due to mutations affecting different states of phosphorylation at sites 
close to the endoplasmic reticulum (ER) retention signal (López-
Hernández et al., 2011).  
GlialCAM was identified as a beta-subunit of MLC1 (Lopez-Hernandez 
et al., 2011a). In MLC patients, expression and localisation of GlialCAM 
has been found to be independent of MLC1. Proper homo-
oligomerization of GlialCAM is a pre-requisite for correct targeting of 
GlialCAM in cellular junctions. On the other hand, MLC1 has been 
shown to require GlialCAM in order to be targeted to astrocyte cell-cell 
junctions. Defective mutations in GlialCAM could also contribute to the 
trafficking defects of MLC1 to cell-cell junctions (López-Hernández et 
al., 2011a,b; Capdevila-Nortes et al., 2013). Therapeutic strategies 
aimed at overexpression of GlialCAM may be beneficial in improving 
surface expression of MLC1-causing mutations in MLC patients, as 
GlialCAM appeared to stabilise S96L-mutation in MLC1 (Lopez-
Hernandez et al., 2011b). 
Channelopathies are a heterogeneous group of genetic or acquired 
origin disorders caused by altered function of ion channel subunits or 
regulatory proteins. MLC has recently emerged as a potential brain 
channelopathy associated to astrocyte dysfunction (Van der Knaap et 
al., 2012; Lanciotti A et al., 2013). With the identified relationship 
between GlialCAM and MLC1 in MLC patients, the possible functions 
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of GlialCAM and MLC1 in MLC patients were found to be linked to 
brain channelopathies associated with astrocyte dysfunction.  
In recent studies, GlialCAM was discovered to be important for 
targeting MLC1 and CLC-2 to specialized glial domains in 
oligodendrocytes in vivo. GlialCAM-mediated targeting of CLC-2 was 
also found to be physiologically relevant to functional activation of CLC-
2, which is important in maintaining water homeostasis in the brain 
(Hoegg-Beiler et al., 2014). In addition, MLC1 was shown to establish 
functional and structural interactions with ion/water channels and 
regulatory proteins (Brignone et al., 2015). Therefore, mutations in 
GlialCAM or MLC1 may affect the function of CLC-2 channels thereby 
causing disturbed water homeostasis in MLC patients (van der Knaap 
et al., 2012; Depienne et al., 2013). 
1.5       Tumor necrosis factor receptor (TNFRs) 
 
1.5.1    Characteristics of TNFRs 
 
A tumor necrosis factor receptor (TNFR) is a trimeric cytokine receptor 
that binds tumor necrosis factors (TNF). The receptor works with 
adaptor proteins (such as TRADD, TRAF, RIP). The type of adaptor 
protein coupled with TNFRs will determine the outcome of the 
response such as inflammation or apoptosis. TNFR-1 mediates most 
cellular responses and is found on most cell types while TNFR-2 is 
found on immune cells. TNFR-1 is a death domain-containing receptor 
and mediates apoptosis (Ashkenazi A and Dixit VM., 1998). In this 
research, we will be focusing on TNFR-1 and more specifically, CD137. 
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TNFR-1 receptors bind to their natural ligand, the homotrimer TNF. 
Upon binding, TNFR-1 forms homotrimers, multimerize to recruit 
TRADD and form distinct platforms for further recruitment of adaptor 
proteins (Hsu et al., 1995). The combination of adaptor proteins will 
determine the distinct pathways for downstream signalling for specific 
cellular responses (Chan F.K.M. et al., 2000).  
1.5.2      TNFRs in cancer development 
Due to the roles of TNFRs and TNFs in cell survival and cell death, the 
crosstalk between the different TNF-induced pathways play a 
significant role in cancer progression. NF-κB suppresses activation of 
the apoptotic gene JNK and promotes expression of anti-apoptotic 
genes, favouring cancer cells survival. Activation of caspase-8 by NF-
κB RIP puts a stop to the cell survival pathway, promoting cell death 
and apoptosis. Thus, the fine balance between the 2 contradicting 
TNF-induced pathways is crucial in determining the fate of the cancer 
cells. Conversely, therapies targeted at the TNF-induced pathways and 
its downstream receptors and participating molecules can aid in cancer 
treatments. 
Playing a major role in inflammation as a pro-inflammation cytokine, 
TNF appears to promote carcinogenesis in cell survival, cell 
proliferation, angiogenesis, invasion and metastasis. In addition, it has 
been found that serum TNF is increased in patients with different 
cancers (Ferrajoli A et al., 2001; Ferrajoli A et al., 2002), which is 
markedly decreased during chemotherapy treatments. With the 
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progression from benign to malignant forms of cancers such as 
prostate cancer, breast cancer and cervical carcinomas, serum TNF is 
found to be elevated as well (Michalaki V et al., 2004; García-Tuñón I 
et al., 2006).   
In a mouse colitis model, mice lacking TNFR-1 or TNF function blocked 
by neutralizing antibody exhibited reduced inflammation and 
attenuation in tumor formation (Popivanova BK et al., 2008). In skin 
carcinogenesis mouse model, blocking or suppressing TNF function 
conferred resistance to skin carcinogenesis (Scott KA et al., 2003; 
Zhaorigetu S et al., 2003). 
Therefore, investigating members of the TNFRs family which TNF acts 
on will shed light on the cell proliferation, cell survival and metastasis of 
cancer cells dependent on the TNFR-TNF induced pathways. 
1.5.3      CD137/CD137L bidirectional signalling pathway 
CD137 is a member of the TNFR superfamily member 9 (TNFRS9), 
alternatively known as 4-1BB. CD137 is usually found on CD8+ T cells, 
dendritic cells, follicular dendritic cells and natural killer cells. CD137L 
is mainly found on antigen presenting cells (APCs). One of the more 
prominent functions of CD137 and CD137 ligand is the co-stimulation 
of T cell activity during cognate interactions. Being a T cell co-
stimulatory molecule, CD137 agonists potently enhance IL-2 secretion 
as well as promote survival and cytolytic activity of T cells. Therefore, 
CD137 and CD137L are suitable targets for tumor immunotherapy. 
Bidirectional signaling system is exhibited amongst many members of 
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the TNF and TNF receptor families. Both receptor and ligand can send 
a signal to their partner molecule but also transmit a signal into the cell 
which they are expressed on. Reverse signaling through CD137L 
enhances the activity of APCs, monocyte activation, proliferation and 
migration, differentiation of human monocytes to dendritic cells and 
subsequent maturation to mature dendritic cells (Schwarz H., 2005). In 
human B cells, CD137L signaling enhances proliferation and 
immunoglobulin secretion mediating co-stimulatory signals that are 
initiated by CD137-expressing helper T cells or follicular dendritic cells. 
1.5.4      Role of CD137 in tumor immunotherapy 
In recent years, tumor immunotherapy has become an interesting field 
as tumors survive by escaping immune surveillance. Understanding of 
generation and regulation of immune responses in tumor 
microenvironment shed insight on the escape mechanism from 
immune surveillance. By understanding the dysregulation of the 
immune system in cancers, immunotherapies can be utilised to target 
the tumor cells.  
One specific approach is to target specific subpopulations of T cells 
that are affected by the tumor cells due to modulation in immune 
responses and activation. Specific co-stimulatory signals can be used 
as targets to increase the receptivity of T cells and enhance T cell 
activation. 
In this regard, CD137 and CD137L prove to play an important role in 
tumor immunotherapy due to their high potential in generating tumor-
37
specific responses in vivo. CD137 was found to be on activated CD4+ 
and CD8+ T cells. The treatment with agonistic CD137 mAb in tumor-
bearing mice promoted effective immune responses (Melero I et al., 
2008). 
1.5.5      Role of CD137 in Hodgkin Lymphoma 
A minority population of malignant HRS cells, surrounded by immune 
infiltrates, is characteristic of HL. Despite the tumor stroma containing 
vast amounts of immune cells, HRS cells were able to survive and 
escape immune surveillance. This is an indication that HRS cells have 
developed potent immune escape mechanisms, allowing them to 
survive in spite of the abundance of immune infiltrates in the tumor 
microenvironment. It has been reported that CD137 is found to be 
highly expressed on HRS cells, which are derived from B cells, while 
normal B cells do not express CD137 (Ho WT et al., 2013). In 48 of 53 
cases of classical HL, CD137 was detected on HRS cells. In a recent 
paper, CD137 was transferred from HRS cells to neighboring HRS 
cells and APCs via trogocytosis. After CD137 became associated with 
CD137L on neighbouring HRS cells and APCs, the CD137–CD137L 
complexes were internalized. CD137-mediated a form of escape from 
immune surveillance through internalization of CD137L from surface of 





1.6      TNFRs and CAMs in cancers 
Expression of CAMs has been reported to be induced by TNF via 
TNFRs (Pu Xia et al., 1998). In inflammatory conditions, CAMs are 
involved in transmigrating leukocytes to sites of inflammation such as 
in inflammatory bowel diseases (IBDs). In addition, stimulation of 
leukocyte adhesion to the endothelium is mediated by TNF-alpha and 
can be explained by the up-regulation of cell adhesion molecules on 
the endothelial cell surface. 
In cancers, expression of CAMs on tumor cells seems to play a role in 
recruiting, adhesion and interactions of leukocytes. In human colon 
cancer, ICAM-1 was found to be expressed by the tumor cells and 
interacted with LFA-1 on the leukocytes. There was a positive 
correlation between expression of ICAM-1 and a peritumoral 
inflammatory infiltrate (Kelly CP et al., 1992). In addition, CAMs have 
been found to interact with leukocytes to direct production of survival 
signals to tumor cells (Küppers R et al., 2012).  
In HL, CAMs have been found aid in adhesion of HRS cells to 
leukocytes to provide survival signals to T cells (Küppers R et al., 
2012).  
Therefore, in order to determine if expression of CAMs on HRS cells 
play a role in adhesion and attraction of leukocytes for subsequent 
inactivation by CD137/CD137L internalization, hepaCAM was 
investigated in CD137-expressing HRS cell lines.  
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CHAPTER 2 AIMS AND OBJECTIVES 
A general screening of several cell lines led to the discovery that 
hepaCAM was found to be expressed in several CD137-expressing 
HRS cell lines. Furthermore, based on the published evidences 
detailing the relationship between TNFRs and CAMs, the role of 
CD137 in HL and the role of CAMs in attracting and adhesion of 
leukocytes in HL, the aims of this study are to 1) Determine the 
expression profile of hepaCAM in HRS cell lines; 2) Determine if 
expression of hepaCAM is CD137-dependent; 3) Investigate if there is 
physical association between hepaCAM and CD137 in HRS cell lines; 
4) Determine if the localisation of hepaCAM in HRS cell lines is CD137-
dependent; 5) Assess the role of hepaCAM in adhesion of HRS cell 
lines to fibronectin, a main component of ECM; 6) Analyze the 
functional role of hepaCAM in infiltration and adhesion of leukocytes 
using HRS spheroids. 
In order to achieve these aims, the objectives of this study would be 1) 
Analyse expression of hepaCAM using Western blot analysis, confocal 
microscopy and flow cytometry with appropriate anti-hepaCAM 
antibodies in CD137-expressing HRS cell lines and their parental cell 
lines; 2) Co-immunoprecipitation to determine the association between 
hepaCAM and CD137 in HRS cell lines; 3) Confocal microscopy and 
flow cytometry to determine the localisation of hepaCAM in HRS cell 
lines; 4) Adhesion assays and cell spreading assays to determine if 
hepaCAM adheres to fibronectin 
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; 5) Adhesion assays to determine the functional role of hepaCAM in 
HRS cell lines in attracting leukocytes; 6) HRS spheroid formation in 


















CHAPTER 3 MATERIALS AND METHODS 
Table 3-1 Antibiotic solutions 
Antibiotics   Concentration 
Ampicillin   100 mg/ml in H20  
Blasticidin   10 mg/ml in H20 
Penicillin Streptomycin  200 units/ml 
All water-soluble antibiotics were filter-sterilized. 
 
Table 3-2 Solutions for preparation of competent cells and bacterial cultivation 
Solution   Concentration 
LB medium   1% Tryptone  
    0.5g Yeast Extract 
    1% NaCl 
 
LB agar    1% Tryptone 
    0.5g Yeast Extract 
    1% NaCl 
    1.5% Agar 
 
 
Table 3-3 Solutions for protein extraction 
Solution   Concentration 
RIPA buffer   50 mM Tris pH 8.0 
    150 mM NaCl 
    1% Triton X-100 
    0.5% NaDOC 
    0.1% SDS 
 
Protease Inhibitor AEBSF, 104 mM 
Aprotinin, 80 μM 
Bestatin, 4 mM 
E-64, 1.4 mM 
Leupeptin, 2 mM 






Table 3-4 Solutions for Western blot 
Solution   Concentration 
2X Laemmli sample buffer 125 mM Tris-HCL pH 6.8 
 4% SDS 
 1.8% β-mercaptoethanol 
 10% Glycerol 
 0.01% Bromophenol blue 
 
5X Laemmli sample buffer 62.5 mM Tris-HCL pH 6.8 
 2% SDS 
 5% β-mercaptoethanol 
 10% Glycerol 
 0.05% Bromophenol blue 
 
10% separating gel (10ml) 2.72 ml H20, 3.75 ml Tris-HCL pH 8.8, 3.33 ml 30%  
 acrylamide/bis solution (29:1; Biorad), 100 ul 10% 
SDS, 100 
 ul 10% APS (ammonium persulfate), 4 ul TEMED 
 
4% stacking gel (4 ml) 2.75 ml H20, 0.5 ml Tris-HCL pH 6.8, 0.67 ml 30%  
 acrylamide/bis solution (29:1; Biorad), 40 ul 10% 
SDS, 40 
 ul 10% APS (ammonium persulfate), 4 ul TEMED 
 
1X SDS-PAGE running buffer 25 mM Tris-HCL 
 0.2 M Glycine 
 0.1% SDS 
 Adjust pH to 8.3 
 
Stripping buffer 25 mM Glycine 
 Adjust pH to 2.0 
 1% SDS 
 
Transfer buffer 25 mM Tris 
 192 mM Glycine 
 20% v/v Ethanol 
  
10X TBS 0.2 M Tris base 
 1.37 M NaCl 
 Adjust pH  to 8.3 
 
1x TBS 20 mM Tris base 
 137 mM NaCl 
 Adjust pH  to 7.6 
 
1X TBS-T 0.1% Tween-20 in 1X TBS 
 




Table 3-5 Solutions for flow cytometry 
Solution   Concentration 
1X PBS    8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4•7H20, 0.24 g 
KH2PO4 
    Adjust pH to 7.2 
 
FACs buffer   1X PBS 
    1% BSA 
 
4% Paraformaldehyde  Add 2 g of praraformaldehyde into 40 ml of 1X PBS.  
    Warm to dissolve. Add 5M NaOH dropwise until 
solution 
    clears. Adjust pH 7.4 and increase volume to 50 ml. 
Filter- 




































3.1 Cell cultures 
 
3.1.1 Cell lines and culture conditions 
8 human cancer cell lines including HRS cell lines (L428, L428-CD137, 
L1236, L1236-CD137, KM-H2 CD137 control, KM-H2 CD137 
knockdown, HDLM-2) and human breast cancer cell line, MCF7, were 
used in the study. All cells were maintained in an incubator at 37⁰C 
with 5% CO2 humidified atmosphere in the appropriate media. 
L428, L428-CD137, L1236, L1236-CD137, KM-H2 CD137 knockdown, 
KM-H2 CD137 control and HDLM-2 cells were maintained in Roswell 
Park Memorial Institute (RPMI)-1640 medium (Sigma) supplemented 
with   
1% L-glutamine and 10% fetal bovine serum (FBS; Gibco BRL, Life 
Technologies, Gaithersburg, MD). 
MCF7 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma. St. Louis, MO) supplemented with 1% L-glutamine and 
10% FBS. 
3.1.2 Passaging cells 
For HRS cell lines, cells were subcultured when they have reached 80-
100% confluence. In a T-75 flask with 10 ml of culture medium, 8 ml of 
cells suspension were removed and the cells in clumps were dispersed 
by repeated pipetting. 8 ml of fresh culture medium was added to the 
remaining cells in the flask to a final volume of 10 ml. 
For MCF7 cell lines, cells were subcultured when they have reached 
80-100% confluence. The culture medium was removed and the cells 
were washed twice with 1xPBS. In a T-75 flask, 1 ml of 1X Trypsin 
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(Gibco BRL) was added and incubated at 37⁰C for 5 min or until the 
cells were detached with gentle shaking. Approximately 5 ml of culture 
medium was added to the flask to stop trypsinization and the cell 
clumps were dispersed by repeated pipetting. 4 ml of cells were 
removed and fresh medium was added to the remaining cells in the 
flask to a final volume of 10 ml. 
In cell counting, 10 ul of the cell suspension was mixed with 10 ul of 0.4% 
trypan blue in PBS on a piece of paraffin film before applying 10 ul of 
the mixture onto a haemocytometer. The number of cells/ml was 
calculated using the following formula: 
 
Number of cells/ml = the average count per square of the 
haemocytometer X 2 (dilution factor) X 104 
 
 
3.1.3 Storing cells 
 
 
Detached cells or cells in suspension were pelleted at 93 x g for 5 min. 
The supernatant was discarded and the cells were resuspended in 
fresh freezing medium consisting of culture medium supplemented with 
8% DMSO and 10% FBS. The cells were stored at a concentration of 
about 2x 106 cells/ml of freezing medium. 1 ml of the cell suspension in 
freezing medium was aliquoted into each cryotube and stored at -80⁰C 
before transferring to liquid nitrogen for long term storage. 
 
3.2 Plasmid constructs 
 
 
The cDNA insert of a plasmid construct was generated by PCR using 
the respective pair of primers listed in Table 3.6. The PCR construct  
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was purified, digested with the appropriate restriction enzymes, and 
cloned in the desired vector by Dr Angela Moh Mei Chung. hepaCAM-
V5 encodes for full length hepaCAM and hCAMΔ263-V5 encodes for 
hepaCAM with truncated cytoplasmic tail. 
Table 3-6 Plasmid constructs 
Construct                      Primer sequence                       Vector 
name    
 
hepaCAM-V5      5’taagcttgccaccatgaagagagaaaggggag3’   pcDNA6B/V5-His 
        5’aggatccggcccaggcgctgatctccacc3’       
hCAMΔ263-V5   5’taagcttgccaccatgaagagagaaaggggag3’   pCDNA6B/V5-His
                 5’tggatccgcaggcacagactgtcacca3’       
 
3.3 Agarose gel electrophoresis 
 
 
DNA was analysed using a 1% agarose gel. A 1% SeaKem LE 
agarose (Bio Whittaker, Walkersville, MD) gel, 0.5 g of agarose was 
added to 50 ml of 1X TAE buffer and microwaved until the agarose was 
completely dissolved. The agarose is subsequently cooled to about 
45⁰C before adding 2.5 ul of 10 mg/ml ethidium bromide (Biorad, 
Richmond, CA). The mixture was poured into a cast with a well comb 
and allowed to solidify. When the gel is set, the comb was removed 
and the gel was submerged in 1X TAE buffer in the electrophoresis 
tank. Gel loading buffer was added to samples before loading into the 
wells. Electrophoresis was carried out at 120V for approximately 40 
min and DNA samples were visualized under UV light. 
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3.4 Phenol/Chlorofoam method 
The DNA eluant was mixed with 1 volume of phenol (Invitrogen, 
Carlsbad, CA), vortexed and centrifuged at 16, 168 x g for 5 min. The 
aqueous layer was transferred into a tube containing 1 volume of 
chlorofoam and mixed thoroughly. Following a centrifugation at 16, 168 
x g for 5 min, the aqueous layer was precipitated with 2.5 volumes of -
20⁰C absolute ethanol and 1/10 volume of 3 M sodium acetate for 30 
min at -80⁰C. The precipitated DNA was pelleted at 16, 168 x g for 15 
min at 4⁰C and washed with 70% ethanol. The pellet was air-dried. 
3.5 Transformation and Cloning  
50 ul of TOP10 competent E. coli cells were thawed at 37⁰C for 1 min 
before adding 1 ng of plasmid into the competent cells. The vial 
containing the mixture was kept on ice for 30 min. In the meantime, 
water bath at 42⁰C was prepared for subsequent steps. After 30 min, 
the vial was incubated for exactly 45 seconds in the 42⁰C water bath 
before replacing back into ice for 2 min. 250 ml of LB broth were added 
into the vial and placed in a 37⁰C shaker for 1 hour at 5 x g. LB agar 
plates containing ampicillin were pre-warmed prior to spreading to 
avoid condensation which may affect colonies growth. After 1 hour, the 
cell pellet was obtained by centrifugation at 371 x g for 5 min and 120 
ul of fresh LB broth containing ampicillin was added. The work area 
was kept sterile by working near a Bunsen burner. The cell pellet was 
pipetted to avoid clumping before spreading onto pre-warmed LB agar 
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plates containing ampicillin. The plates were inverted and incubated at 
37⁰C overnight (12-18 hours).  
3.6 Plasmid miniprep kit 
An aliquot of bacterial glycerol stock or a bacterial colony was 
inoculated in 3 ml of LB broth supplemented with ampicillin. The 
inoculated bacteria were cultured at 37⁰C overnight in a shaker at 5 x g. 
3 ml of bacteria in LB broth supplemented with ampicillin were pelleted 
by centrifugation at 16, 168 x g for 1 min. Plasmid extraction was 
carried out using the Wizard Mini-prep kit (Promega) according to 
manufacturer’s protocols. The bacteria pellet was resuspended in 250 
ul of Cell Resuspension solution thoroughly to prevent clumps before 
lysing in 250 ul of Cell Lysis solution. The mixture was inverted gently 
several times to obtain a clear and viscous solution. 10 ul of Alkaline 
Protease solution was added into the solution, mixed well and 
incubated for 5 min. Neutralization solution was added to precipitate 
bacterial cell wall fragments, proteins and chromosomal DNA. The 
mixture was centrifuged at 16, 168 x g for 10 min. The supernatant 
containing plasmid DNA was transferred to a spin column and 
centrifuged at 16, 168 x g for 1 min to retain DNA on the spin column. 
The column was washed with 750 ul and a subsequent 250 ul of wash 
buffer containing ethanol and centrifuged at 16, 168 x g for 1 min to 
removed excess wash buffer. Plasmid DNA was eluted using 50 ul of 




3.7 Determination of nucleic acid concentration 
 
 
The concentration and purity of DNA and RNA were determined by 
measuring their optical density (OD) at 260 and 280 nm. The 
concentration of DNA or RNA was calculated using the molar extinction 
coefficient (OD260 = 1 = 50 μg/ul for DNA or OD260 = 1 = 40 μg/ul for 
RNA) as shown below. 
 
OD260 X dilution factor X 50 μg/ul = Concentration of DNA μg/ul 
 
OD260 X dilution factor X 40 μg/ul = Concentration of RNA μg/ul 
 
 
The ratio of OD260/ OD280 was used to determine the purity of nucleic 
acids. Pure DNA or RNA has a ratio of approximately 1.8-2.0. A ratio 
less than 1.8 indicates that there may be proteins or other UV 
absorbers in the samples. A ratio more than 2.0 indicates that the 
samples may be contaminated with phenol or chlorofoam. 
 
3.8 Bacterial glycerol stock 
 
Glycerol was diluted to 50% in H20 and filter-sterilized. 150 ul of 50% 
glycerol was added to 350 ul of bacterial culture. The mixture was 
stored at -80⁰C. 
 
3.9 Transient and stable transfection 
 
 
Cells were seeded the day prior to transfection to reach a density of 
50-80% on day of transfection. Transfections were carried out using 
Lipofectamine and Lipofectamine Plus reagents (Invitrogen) according 
to the manufacturer’s protocols. Cells were transfected with DNA pre-
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complexed with Lipofectamine and Lipofectamine Plus reagents in 
appropriate serum free media for 3 hours. Subsequently, the medium 
containing the complexes and reagents were removed and replaced 
with appropriate medium supplemented with 10% FBS. 
For stable transfections, cells were transfected in 35-mm plates before 
reseeding into 100-mm plates and T75 flasks after 24 hours of 
transfection and selection under 10 μg/ml of blasticidin (Invitrogen). 
The cell culture was maintained for 2 weeks. Subsequently, the cells 
were trypsinised, single cells were picked under a microscsope and 
transferred into individual wells of a 24-well plate containing parental 
cells at 20-30% confluence. The parental cells were initially added to 
provide growth factors to the stable cell lines. The cells were allowed to 
grow without selection medium for a few days to allow the parental 
cells to grow alongside the transfected cells. Thereafter, the cells were 
then kept in selection medium to eliminate the parental cells and allow 
the trasnfected cells to reach 80-100% confluence. The individual 
clones were then tested using Western blot to confirm the expression 
of the desired protein. Cell homogeneity was tested using 
immunocytochemistry. The positive clones were then expanded to 
obtain stable cell lines. 
For transient transfections, the transfected cells were cultured without 
antibiotic selection for 24-48 hours before assaying. 
3.10  Protein purification using NI-NTA magnetic agarose beads 
NI-NTA magnetic agarose beads were added to supernatant containing 
HIS-tagged proteins to pull down the proteins. The mixture was 
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incubated at 4⁰C and rotated at 25 rpm for 2 hours. His-tagged proteins 
attached to the magnetic agarose beads were pulled down using a 
magnetic strip and the supernatant was removed. The magnetic 
agarose beads were washed with wash buffer twice for 1 min each 
before eluting with 50 ul of elution buffer. Concentrations of protein 
were determined. 
 
Table 3-7 Solutions for protein purification using NI-NTA magnetic 
agarose beads  
Solution   Concentration 
Wash buffer   1X PBS 
    0.05% Tween 20 
    Adjust to pH 8.5 
 
Elution buffer   0.345 g NAH2PO4 
    0.877 g NaCl 
    0.034 g Imidazole 
    Adjust to pH 8.0 
 
 
3.11     Immunocytochemistry 
 
3.11.1     Co-localisation of hepaCAM and CD137 in HRS cells 
 
CD137-expressing, hepaCAM-expressing HRS cells were fixed using 4% 
PFA at 37⁰C for 10 min, permeabilized with 0.2% Triton X at room 
temperature for 10 min and blocked with 1% BSA at 37⁰C for 1 hour. 
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Protein expression of hepaCAM was detected using mouse anti-
hepaCAM antibody (R&D, MAB 4108, 1:50 dilution) at 4⁰C overnight 
and subsequently, FITC-conjugated goat anti-mouse IgG antibody 
(Invitrogen, Alex Fluor 488, 1:50 dilution) at room temperature for 2 
hours. Protein expression of CD137 was detected using PE-conjugated 
mouse anti-CD137 antibody (BioLegend, 4B4-1, 1:25 dilution) The cells 
were spun onto a polylysine coated slide. A drop of mountant was 
added onto the slide and a cover slip was placed over it. The cells were 
visualized using Confocal LSM 510 and Zeiss FV1000 confocal 
microscopes with sectioning performed at 0.5 µm. 
 
3.12  Cell adhesion assay of HRS cells to fibronectin 
In cell adhesion assays, HRS cells were treated with isotype control or 
anti-hepaCAM antibodies at room temperature for 2 hours on rotation. 
Subsequently, the cells were added to plates coated with fibronectin 
(10 μg/ml; Santa Cruz) as seen in Figure 3-1. The cells were incubated 
in the incubator at 37⁰C with 5% CO2 humidified atmosphere for 5-10 
min before detachment with gentle flushing. The attached cells and 
floating cells were placed into separate tubes containing 10 ul of 





Figure 3-1 Cell adhesion assay of HRS cells to fibronectin 
3.13  Cell spreading assay of HRS cells on fibronectin  
In cell spreading assay, cells were treated with isotype control or anti-
hepaCAM antibodies at room temperature for 2 hours on rotation. 
Subsequently, the cells were added to plates coated with fibronectin 
(10 μg/ml; Santa Cruz) as seen in Figure 3-2. Unspread cells were 
defined as round cells while spread cells were defined as cells with 
extended processes. The cells were stained with 1 ul of Cell mask 
orange plasma membrane stain (Invitrogen) diluted in 1 ml of 1X PBS 
for 5-10 min before visualizing with Zeiss FV1000 confocal microscope. 
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3.14 Preparation of whole cell extracts for Western blot analysis 
 
 
Suspension cells were pelleted at 580 x g for 10 min. Cell pellets were 
washed with 1X PBS twice before adding radioimmunoprecipitation 
assay (RIPA) buffer. The mixture was pipetted up and down to ensure 
uniform suspension of the cell pellet. The suspension was vortexed for 
a few seconds and incubated on ice for 10 min before centrifugation at 
16, 168 x g 4⁰C for 10 min. The supernatant was collected and mixed 
with equal volume of 2X or 5X Laemmli sample buffer and boiled for 5 
min before Western blot analysis. 
 




The Bradford assay is a dye-binding assay based on differential color 
change of Coomassie blue G dye when it is bound to protein. The 
concentrations of proteins were determined by Bradford assay (Biorad) 
at OD595. One volume of Bradford Dye Reagent was diluted in 4 
volumes of H20 as the working solution. 1 ul of protein sample was 
diluted in 9 ul of 1X PBS before adding 200 ul of the working solution of 
Bradford Dye Reagent. A standard curve was plotted by measuring the 
absorbance of BSA at different concentrations. The concentrations of 






3.16      Western blot analysis 
 




Protein samples were denatured using 1/10 volume of beta-
mercaptoethanol at 99⁰C for 5 min. The denatured proteins samples 
were loaded in 10% SDS-PAGE gel and separated by running in 1X 
SDS-PAGE running buffer at 15 V/cm for 70 min. 
 
3.16.2      Protein Transfer 
 
 
Following electrophoresis to resolve the protein samples, proteins were 
transferred from the polyacrylamide gel onto PVDF membrane (Biorad) 
using Biorad’s Mini Trans-Blot Electrophoretic Transfer Cell. The 
Whatman filter papers, fiber pads, gel and membrane were assembled 
as illustrated in the set-up in Figure 3-3. The proteins were transferred 
from the gel (cathode) to the membrane (anode) at 10 V/cm for 60 min 
in Towbin transfer buffer containing 0.1% SDS with an ice block placed 
in the transfer tank to enable efficient transfer. 
 
Figure 3-3 Assembly for protein transfer.  
Adopted from www. http://www.abcam.com/protocols/general-
western-blot-protocol 
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3.16.3      Western blot 
 
 
The membrane was rinsed with 1X TBS/T and blocked in 5% non-fat 
milk at room temperature for 1 hour on the shaker. The blots were 
incubated with primary antibodies overnight at 4⁰C. Primary antibodies 
used included mouse anti-hepaCAM monoclonal antibody (1:500 
dilution), mouse anti-CD137 monoclonal antibody (BBK2; 1:2000 
dilution) or mouse anti-GAPDH antibody (Santa Cruz; 1:1000 dilution). 
Blots were then washed 3 times with 1X TBS-T, 5 min each before 
being incubated in the goat anti-mouse horseradish peroxidase-
conjugated secondary antibody (Santa Cruz; 1:2500 dilution) for 2 
hours at room temperature. The blots were washed 4 times with 1X 
TBS-T, 5 min each before detecting enzymatic activity using 
chemiluminescence luminal reagent (Santa Cruz) and autoradiography. 
 
3.16.4      Stripping Western blot membranes 
 
 
Western blots were stripped using Stripping buffer for 15 min on a 
shaker before washing with 1X TBS for 10 min. The blots were 
subsequently air dried before keeping at 4⁰C for future protein 
detection. 
 
3.17      Chemical cross-linking 
Chemical crosslinking offers a direct method of identifying both 
transient and stable interactions which involves the formation of 
covalent bonds between two proteins. A single suspension of cells was 
incubated in PBS and DMSO containing 3,3’-Dithiobis 
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(sulphosuccinimidyl propionate) (DTSSP; Pierce) to a final 
concentration of 2 mM at room temperature for 30 min. The reaction 
was quenched with 20 mM Tris-HCl pH 7.5 for 15 min. Subsequently, 
cell lysates were prepared in RIPA buffer and analysed using co-
immunoprecipitation methods. 
 
3.18       Co-Immunoprecipitation 
 
Immunoprecipitation was used to determine the presence of protein-
protein interactions. Cell lysates were prepared in 1% NP40 
supplemented with protease inhibitor and precleared with Protein G-
agarose beads (Santa Cruz) at 4⁰C for 1 hour on rotation. The 
precleared lysates were mixed with Protein-G agarose beads and 
appropriate antibody in 1% NP40 supplemented with protease inhibitor, 
and incubated overnight at 4⁰C. The agarose beads were washed 4 
times with 1% NP40 and resuspended in 30 ul of 2X Laemmli sample 
buffer, boiled at 99⁰C for 5 min and the eluted proteins previously 
bound to the agarose beads were subjected to Western blot analysis. 
 
3.19      Flow cytometry 
 
3.19.1      Analyse expression of hepaCAM on HRS cells 
 
 
Flow cytometry was carried out to determine the expression of 
hepaCAM on cell surfaces of HRS cells. HRS cells were fixed with 4% 
PFA at 37⁰C for 10 min and blocked with 1% BSA at 37⁰C for 1 hour. 
Subsequently, the cells were incubated with mouse anti-hepaCAM 
antibody (R&D; 1:50 dilution) at 4⁰C overnight and washed 3 times with 
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1% BSA in 1X PBS. The cells were incubated in the dark with FITC-
conjugated anti-mouse IgG (1:50 dilution) at room temperature for 2 
hours. The cells were washed 3 times with 1% BSA in 1X PBS. Flow 
cytometry was performed on a CYAN ADP Analyzer (Beckman Coulter, 
Brea, CA) with Summit data acquisition and analysis software. 
Nonspecific staining was controlled by isotype matched antibodies. 
 
3.19.2      Determine % of attached cells using counting beads 
 
 
CountBright Absolute Counting Beads (ThermoFisher Scientific) were 
used for counting cells analysed by flow cytometry. The nominal 
microsphere concentration is 50, 000 beads per 50 ul. For absolute 
counts, 10 µl of the microsphere suspension is added to a specific 
volume of sample. Therefore, the ratio of sample volume to 
microsphere volume is known. The volume of sample analyzed can be 
calculated from the number of microsphere events, and can be used 
with cell events to determine percentage of attached cells.  
For example, 10 µl of the microsphere suspension containing 10, 0000 
counting beads were added into each sample. 1000 counting beads 
were gated and cell events were determined. As the sample contained 
10, 000 counting beads, absolute cell numbers would be calculated 






Calculation of absolute cell numbers: 
A/B X C = Absolute cell numbers 
 
Where: 
A = number of cell events 
B = number of bead events 
C = assigned bead concentration of the lot (50, 000 per 50 µl) 
  
Calculation of percentage of attached cells 
Percentage of attached cells =  
A / (A+B) X 100 
 
Where: 
A = absolute number of attached cells 
B = absolute number of floating/unattached cells 
 




PBMCs were used in adhesion assays and subsets of PBMCs (e.g. T 
cells, B cells and monocytes) were analysed using staining of specific 
immune cell markers (e.g. CD3 for T cells, CD14 for monocytes and 
CD20 for B cells respectively).  PBMCs were stained with the 
appropriate antibody against the specific immune cell markers (1:20 
dilution) for 1 hour and washed 3 times with 1% BSA in 1X PBS. 
PBMCs were analysed using flow cytometer to determine the subsets 
of PBMCs in adhesion assays. 
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3.20      Adhesion assay of hepaCAM to PBMCs 
 
3.20.1      Adhesion of hepaCAM protein to PBMCs 
 
 
10 µg /ml of hepaCAM protein or BSA protein was coated onto 24-wells 
plates overnight at 4⁰C. PBMCs were activated with 10 ng/ml of OKT-3 
prior to adding to the coated plates. After 5-10 min of incubation at 
37⁰C, floating and attached cells were collected. 10 ul of counting 
beads were added to the samples before analysis was carried out 
using Fortessa Flow Cytometer. Subsequently, subsets of PBMCs 
were stained according to Section 3.19.3.  
 
3.20.2      Adhesion of HRS cells to PBMCs 
 
 
10 µg /ml of fibronectin in 1X PBS was coated onto 24-wells plates 4⁰C 
overnight. Subsequently, 2 x 106/ ml of  HRS cells were immobilized 
onto the fibronectin coated plates overnight in the incubator prior to 
carrying out adhesion assays using PBMCs. A confluent layer of HRS 
cells (80-100% confluency) was obtained before carrying out adhesion 
assays using PBMCs. This is to ensure that PBMCs were indeed 
attached to HRS cells instead of fibronectin coated onto the plates. 1 x 
106 / ml PBMCs were activated by 10 ng/ml OKT-3 for 24-48 hours 
prior to addition to the attached HRS cells on the plates. Pre-treatment 
of HRS cells with 10 µg/ml of anti-hepaCAM blocking antibody or 
isotype control, MOPC21, was used to block hepaCAM sites at 37⁰C 
for 2 hours. Subsequently, activated PBMCs were added to pre-treated 
HRS cells and incubated at 37⁰C for 5-10 min. Both floating and 
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attached cells were collected, using counting beads to record 
percentage of atFtached cells. Analysis was carried out using Fortessa 
Flow Cytometer as described in Section 3.19.3. 
 
3.21      Infiltration of PBMCs in HRS spheroids 
 
3.21.1      Hanging drop method 
 
 
1x10^6 HRS cells were grown using the hanging drop method to obtain 
spheroids. 20 ul of cell suspension was cultured as droplets on the lids 
of 100 mm culture dishes and 1.5 ml of 1 X PBS was added into the 
culture dishes to prevent the cell droplets from drying. The cell droplets 
were cultured for 48 hours and washed with media before further 
culturing in 8 wells borosilicate chambers for 24 hours. 
 
3.21.2      Infiltration of PBMCs 
 
 
To determine if the infiltration and attraction of PBMCs to spheroids 
were contributed by hepaCAM, HRS spheroids were treated with 
isotype control (MOPC21) or hepaCAM blocking antibody (MAB 4108) 
for 2 hours prior to addition of pre-OKT3 activated PBMCs. HRS 
spheroids were stained with red cell mask while PBMCs were stained 
with CFSE. Analysis was done using FV1000 confocal microscope and 






3.22 Bioinformatics and statistical analysis 
 
3.22.1 Flow cytometry 
 
 
Flow cytometry analysis was carried out using Summit software for 
CYAN Flow Cytometer and using Flowjo software for Fortessa Flow 
Cytometer. Mean and median fluorescence intensity were obtained 
using the total mean and media fluorescence provided by the 
calculations done by the software. 
 
3.22.2 Confocal microscopy 
 
Confocal microscopy images were processed using LSM Image 
Browser for LSM 510 confocal microscope and using Olympus 
Fluoview for FV 1000 confocal microscope. Calculations for 
fluorescence intensities were calculated using IMAGEJ. 
 
3.22.3 Statistical differences 
 
 
In this research paper, T-test was used to determine the statistical 
differences between control and sample groups for the experiments 
carried out. Error bars were computed using 1± standard deviation. 
The experiments were carried out in triplicates or quadruplicates to 






CHAPTER 4 RESULTS 
4.1 Influence of hepaCAM expression by CD137 in HRS cell 
lines  
The expression of hepaCAM protein was screened in various parental 
and transfected HRS cell lines of L428, L1236, KM-H2 and HDLM-2. 
CD137-deficient L428 and L1236 cells were stably transfected with 
CD137 and labelled as L428-CD137 and L1236-CD137, respectively. 
On the other hand, the endogenous expression of CD137 was silenced 
in KM-H2 cells (KM-H2-CD137 knockdown), with the empty vector-
transfected KM-H2 cells serving as control (KM-H2 CD137 control).  
HDLM-2 cells which expressed CD137 endogenously were included as 
a positive control. Western blot analysis showed that cells expressing 
CD137 exhibited a significantly higher expression of hepaCAM 
compared with cells lacking CD137. 
In HRS cell lines over-expressing CD137 (L428-CD137 and L1236-
CD137), the expression of hepaCAM was approximately 2-3 times 
higher than their parental cell lines (L428 and L1236) that do not 
express CD137. Conversely, suppression of CD137 (KM-H2-CD137 
knockdown) drastically reduced the expression of hepaCAM by 3.4 
times compared to KM-H2 CD137 control cells (Figure 4-1). GAPDH 
(37 kDa) was used as the loading control. 
Consistently, confocal microscopy data indicated higher levels of 
hepaCAM expression in CD137-expressing cell lines (L428-CD137, 
L1236-CD137 and KM-H2 CD137 control) compared to CD137-
deficient cell lines (L428, L1236 and KM-H2-CD137 knockdown) as 
detected by monoclonal anti-hepaCAM antibodies (Figure 4-3).  
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4.2 Co-localisation of hepaCAM and CD137 on surfaces of 
CD137-expressing HRS cell lines  
 
 
Quantitative measurements of surface expression of hepaCAM were 
carried out using flow cytometry analysis (Figure 4-2). HRS cells were 
stained for hepaCAM using the monoclonal hepaCAM antibody and 
detected using a secondary antibody conjugated to FITC. The surface 
expression of hepaCAM on CD137-expressing HRS cell lines was 2 
times higher than the CD137-deficient cell lines. Knockdown of CD137 
in KM-H2 cells significantly decreased the expression of hepaCAM.  
Confocal microscopy analysis revealed co-localization of hepaCAM 
and CD137 (Figure 4-3).  In L438 and L1236 parental cell lines, 
hepaCAM was weakly localized on the plasma membrane in the 
absence of CD137. In contrast, overexpression of CD137 in these cell 
lines (L428-CD13, L1236-CD137) significantly induced hepaCAM 
expression, accompanied with an intense staining of the cell adhesion 
molecule on the cell surface. 
Moreover, both CD137 and hepaCAM appeared colocalized on the 
plasma membrane of L428-CD137 and L1236-CD137 cells. 
Consistently, silencing of CD137 in KM-H2 cells resulted in a reduced, 
diffused expression of hepaCAM. 
These observations further compounded the data obtained from flow 
cytometry pertaining to the higher surface expression of hepaCAM in 

































































Figure 4-1 hepaCAM protein expression levels in HRS cell lines
(a) Western blot analysis of hepaCAM in HRS cell lines. 50 µg of 
protein was loaded in each lane and visualized using ECL. 
hepaCAM was detected at 75 kDa and the loading control, GAPDH, 
was detected at 37 kDa. The experiments were carried out in 3 
separate experiments with similar results. (b) Densitometry of 
protein bands in arbitrary units. Intensities of immunoreactive bands 
on western blots were quantified by densitometric analysis using 
IMAGEJ, comparing hepaCAM expression in CD137-expressing 
HRS cell lines to CD137-deficient HRS cell lines. The readings were 
measured in pixel intensities and represented in graphs. The 
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Figure 4-2 Increased surface expression of hepaCAM in CD137-
expressing HRS cells
(a) Flow cytometry analysis of hepaCAM in HRS cells. HRS cell lines 
were stained with monoclonal hepaCAM antibody or MOPC21 as 
isotype control, and subsequently stained with a secondary FITC-
conjugated antibody. The experiments were carried out in 3 separate 
experiments with similar results. Grey: Isotype control, Black: anti-
hepaCAM, MFI1: Mean Fluorescence Intensity, MFI2: Median 
Fluorescence Intensity (b) Percentage of cells staining positive for 
hepaCAM was analysed. The experiments were carried out in 3 
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Figure 4-3 Expression and co-localisation of hepaCAM
and CD137 in HRS cell lines
Confocal microscopy was used to analyse the expression and 
localization of hepaCAM and CD137 in HRS cells. Monoclonal 
anti-hepaCAM antibody and FITC-conjugated secondary 
antibody were used to stain for hepaCAM. PE-conjugated 
anti-CD137 antibody was used to stain for CD137. DAPI was 
used to counterstain the nucleus. The experiments were 
carried out in 3 separate experiments with similar results. 
Blue: DAPI, Green: hepaCAM, Red: CD137. Co-localisation 
was indicated by merged signals (orange or yellow) and white 
arrows.
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4.3 Physical interactions between hepaCAM and CD137 in vitro 
Co-immunoprecipitation experiments were employed to determine the 
possible physical interactions between hepaCAM and CD137 in HRS 
cell lines, L1236-CD137 and KM-H2 CD137 control. Anti-CD137 
antibody (Clone BBK-2) was used to pull down CD137 in HRS cell 
lysates and MOPC-21 was used as the isotype control. The expression 
of hepaCAM (75 kDa) and CD137 (37 kDa) was detected using 
Western blot analysis.  The sample which pulled down CD137 using 
Protein G agarose beads had significantly higher hepaCAM protein 
compared to the sample with isotype control (fi). The results showed 
that hepaCAM coimmunoprecipitated with both exogenously- (L1236-
CD137) and endogenously-expressed CD137 (KM-H2 CD137 control).  
To analyse the regions of hepaCAM responsible for interacting with 
CD137, wildtype hepaCAM and tailless hepaCAM were transfected 
separately into the MCF7 cell line overexpressing CD137 (MCF7-
CD137). Tailless hepaCAM was constructed without the cytoplasmic 
tail and consisted of amino acids 1-263 of the 416 amino acids 
encoded by Gene HEPACAM.  Anti-CD137 antibody (clone BBK-2) 
was used to pull down CD137 in the cell lysates and hepaCAM was 
probed using Western blot analysis. Full-length hepaCAM (75 kDa), but 
not tailless hepaCAM (~60 kDa), bound CD137 as shown in Figure 4-5, 
suggesting that the cytoplasmic tail of hepaCAM is crucial in 
interactions with CD137.                                                                               
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Figure 4-4 Physical interactions between hepaCAM and   
CD137 in CD137-expressing HRS cells
Co-immunoprecipitation of HRS cells expressing CD137 and 
hepaCAM. Cell lysates were immunoprecipitated with anti-
CD137 (Clone BBK2) and analysed with Western blot analysis 
using hepaCAM antibodies as indicated. MOPC21 was used as 
an isotype control. hepaCAM was probed at 75 kDa, CD137 
was probed at 37 kDa and Fc domains of antibodies were 
probed at 50 kDa. FC domains of antibodies were used as the 
loading control. The experiments were carried out in 3 separate 
experiments with similar results. Left panel: L1236-CD137, 
Right Panel: KM-H2 CD137 control. Lane 1: Cell Lysates, Lane 
2: MOPC21 agarose beads, Lane 3: anti-hepaCAM agarose 
beads.
2 3 2 3


















Figure 4-5 Mutation studies of physical interactions 
between hepaCAM and CD137 in CD137-expressing, 
hepaCAM-expressing MCF-7 cells
In co-immunoprecipitation experiments, CD137 was pulled down 
using cell lysates of CD137-expressing, hepaCAM-expressing 
MCF-7 cells before probing for hepaCAM using western blot 
analysis. MOPC21 was used as the isotype control and anti-
CD137 (clone BBK2) was used to pull down CD137. MOPC21 
agarose beads were loaded into Lane 1 and BBK2 agarose 
beads were loaded into Lane 2. Fc domains of antibodies were 
used as loading control. The experiments were carried out in 3 
separate experiments with similar results. Left panel: wildtype 
hepaCAM, Right Panel: hepaCAM-tailless. CL stands for cell 
lysates.
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 4.4      Adhesive properties of hepaCAM 
4.4.1 Adhesive properties of hepaCAM on fibronectin 
Although previous work has demonstrated that hepaCAM promoted 
adhesion of various cell types on fibronectin, the adhesive role of 
hepaCAM in HRS cells was undetermined.  
Analysis of hepaCAM-mediated adhesion to fibronectin in HRS cells 
was carried out using fibronectin coated plates and anti-hepaCAM 
blocking antibodies. As shown in Figure 4-6, CD137-expressing HRS 
cells (L428-CD137, L1236-CD137 and KM-H2 CD137 control) showed 
a stronger affinity to adhere to fibronectin compared to CD137-deficient 
cell lines (L428, L1236 and KM-H2-CD137 knockdown).  Pre-treatment 
of cells with 10 µg/ml of hepaCAM blocking antibodies for 2 hours prior 
to the cell adhesion assays decreased adhesion of HRS cells to 
fibronectin compared to isotype control antibodies. Similarly, 
hepaCAM-mediated cell spreading of HRS cells on fibronectin was 
abrogated when anti-hepaCAM antibodies were used to block 
hepaCAM sites (Figure 4-7). Therefore, hepaCAM blocking antibodies 
managed to inhibit the adhesive effects of hepaCAM on HRS cells to 
fibronectin, indicating that hepaCAM played a role in adhesion and cell 
spreading to fibronectin in HRS cells. 
4.4.2 Adhesive properties of hepaCAM protein to PBMCs 
In HRS cells, cell adhesion molecules such as ICAM-1 and VCAM-1 
have been found to attract PBMCs to the tumor microenvironment for 
subsequent inactivation of immune cells (Küppers R et al., 2012; 
Höpken 2014). In order to determine if hepaCAM played a role in 
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 attracting PBMCs, OKT3-treated PBMCs were cultured on wells, 
coated with either purified hepaCAM protein or BSA protein (control) 
overnight, for 5-10 min in the incubator at 37⁰C 5% humidified 
atmosphere. Using flow cytometry, attached cells were stained using 
markers for T cells (CD3), B cells (CD20) and monocytes (CD14). 
OKT3 activated PBMCs were found to adhere better to hepaCAM 
protein compared to control plates as shown in Figure 4-8. 
4.4.3 Adhesive properties of hepaCAM in HRS cells to PBMCs 
In HRS cells, hepaCAM was found to be highly expressed on cell 
surface of CD137-expressing HRS cells. In order to determine if the 
expression of hepaCAM on HRS cells contribute to adhesion of 
PBMCs, HRS cells, immobilized onto fibronectin coated plates and pre-
treated with hepaCAM blocking antibody to block hepaCAM sites, were 
co-cultured with OKT-3 activated PBMCs. Neutralization of hepaCAM 
on HRS cells inhibited adhesion of PBMCs as seen in Figure 4-9.  
Thus, the result implied that hepaCAM on HRS cells played a role in 
adhesion of leukocytes, which is in agreement with the role of other 
CAMs in other tumors and HL.  
In order to mimic more closely the recruitment and establishment of the 
extended tumor stroma in HL, we generated spheroids from L428-
CD137 and L1236-CD137 cells which expressed higher levels of 
hepaCAM. These spheroids were generated by culturing droplets of 
cell suspension onto cell culture dish lids using the hanging drop 
method. These spheroids were then co-cultured with activated PBMCs 
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 in the presence of isotype control or neutralizing anti-hepaCAM 
antibodies. After 2 hours, the number of PBMCs that had migrated into 
the spheroids was quantified by confocal microscopy (Figure 4-10A). In 
both L428-CD137 and L1236-CD137 cell spheroids, neutralization of 
hepaCAM reduced the number of infiltrated PBMCs significantly. In 
addition, 3D images provided cross-sectional views of the cell 
spheroids (Figure 4-10B). The increased infiltration of PBMCs 
mediated by hepaCAM was illustrated by the quantification of pixel 
intensities using IMAGEJ seen in Figure 4-10C.  This observation 
demonstrated that CD137-induced hepaCAM expression in HRS cells 
contributes to the HRS cell-mediated recruitment of leukocytes, a 




































Figure 4-6 Adhesive properties of hepaCAM to fibronectin
Cell adhesion assays demonstrating hepaCAM adhesion to 
fibronectin. 10 µg/ml of monoclonal hepaCAM blocking antibody 
and MOPC21 (isotype control) were used to treat the HRS cells. 
HRS cells were added to fibronectin coated plates for 5-10 min 
at 37⁰C. Percentage of attached cells was counted using 
counting beads and analysed using flow cytometry. The 
experiments were carried out in 3 separate experiments with 
similar results. Error bars represent one standard deviation from 
the mean. T-test, n=3, p<0.05. * significant at p<0.05.
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Figure 4-7 Cell spreading properties of hepaCAM to fibronectin
Cell spreading assays performed on hepaCAM-expressing HRS 
cells. 10 μg/ml  of monoclonal hepaCAM blocking antibody or 
MOPC21 (isotype control) were used to treat the HRS cells prior to 
performing cell spreading assays. Cell mask was used to stain the 
cells for visualisation purposes and images were taken at 60X 
magnification with 2X zoom using Carl Zeiss FV1000 confocal 
microscope. Cell spreading are indicated by the white arrows. The 























































Figure 4-8 Adhesive properties of purified hepaCAM protein 
to activated PBMCs
Adhesion assays performed using purified hepaCAM protein and 
activated PBMCs. 10 μg/ml of purified hepaCAM protein or BSA 
were coated onto 24-wells plates prior to adhesion assays using 
PBMCs activated with 10 ng/ml OKT3. Absolute number of 
attached cells was counted using counting beads and analysed 
using flow cytometry. Error bars were constructed using 1±
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Figure 4-9 Adhesive properties of hepaCAM in HRS cells 
to activated PBMCs
Adhesion assays performed using hepaCAM-expressing HRS 
cells and activated PBMCs. 10 µg/ml of monoclonal hepaCAM
blocking antibody was used to block hepaCAM sites on HRS 
cells. MOPC21 were used as the isotype control. HRS cells 
were immobilized onto fibronectin coated plates prior to 
adhesion assays with OKT-3 activated PBMCs. Attached 
PBMCs were counted using counting beads and analysed by 
flow cytometry. Error bars were constructed using 1 ±
standard deviation. T-test, n=3, p<0.05. * significant at p<0.05.
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Figures 4-10 Infiltration of PBMCs into HRS spheroids
Analysis of infiltration of PBMCs into HRS spheroids using confocal 
microscopy. Droplets of HRS cell suspension were cultured on lids of culture 
dishes for 48 hours using the hanging drop method to obtain HRS spheroids. 
10 μg/ml of monoclonal hepaCAM antibody or MOPC21 (isotype control) was 
used to treat the HRS spheroids for 2 hours in order to block hepaCAM sites. 
CFSE pre-stained PBMCs were activated with 10 ng/ml of OKT3 for 24-48 
hours prior to incubation with the HRS spheroids. Cell mask were added to the 
mixture of both HRS spheroids and PBMCs, Therefore, HRS spheroids 
appeared red (red cell mask) while PBMCs appeared yellow (green CFSE + 
red cell mask). (a) 2D images with size marker at 50 µm and (b) 3D images 
with size marker at 30 µm, were captured to confirm the infiltration of PBMCs 
in the HRS spheroids. The side panels represent the cross-sectional views of 
the HRS spheroids. Images were taken at 60X magnification with 2X zoom 
using Carl Zeiss FV1000 confocal microscope. (c) Infiltrating PBMCs in HRS 
spheroids were quantified using IMAGEJ. Pixel intensities of PBMCs (yellow) 
were quantified as a percentage of the pixel intensities of HRS spheroids (red). 
The experiments were carried out in 3 separate experiments with similar 
results. Error bars were constructed using 1± standard deviation. T-test, n=3, 
p<0.05. * significant at p<0.05.
C
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 CHAPTER 5 DISCUSSIONS 
In recent years, the role of cell adhesion molecules in signal 
transduction, metastasis and attraction, and adhesion of leukocytes in 
tumor microenvironment have provided a different perspective on the 
escape mechanisms from immune surveillance employed by the 
tumor cells (Moh MC et al., 2009; Albeda SM et al., 1993; Paschos 
KA et al., 2009). In addition, cell adhesion molecules belonging to the 
immunoglobulin superfamily, such as MCAM, NCAM, ALCAM and 
L1CAM, are often found to be up-regulated in metastasizing tumors to 
provide mechanical stability to migrating tumor cells (Wai Wong C et 
al., 2012). 
In this regard, Hodgkin Lymphoma was investigated as the disease is 
characterised by a small subpopulation of malignant HRS cells 
surrounded by a large amount of immune infiltrate (Küppers R et al., 
2009). Despite the high density in immune cells surrounding the 
tumor cells, HRS cells were still able to survive under the host’s 
immune surveillance. A previous study carried out by our laboratory 
revealed a possible mechanism for T cell inactivation through the 
internalization of CD137/CD137L (Ho et al., 2013). However, the 
mechanism for the attraction and adhesion of leukocytes on HRS 
cells prior to inactivation is still unknown. In cancers, cell adhesion 
molecules are often involved in attraction of leukocytes to tumor sites 
to be subsequently inactivated. Interestingly, CD137 has been also 
found to up-regulate VCAM-1 and ICAM-1 in endothelial cells in tumor 
microenvironment to attract leukocytes (Palazón A et al., 2011). 
91
 In this study, we focused on the functions of a novel immunoglobulin-
like adhesion molecule, hepaCAM, in association with CD137 in HL 
disease. 
5.1 Expression of hepaCAM is regulated by CD137 
HRS cells have been known to survive in tumor stroma overwhelmed 
by immune infiltrates. Ectopic expression of molecules such as CD30 
and CD137 were found to aid HRS cells in cell-cell contacts and 
cytokine signaling, enabling survival of HRS cells and escape from 
immune surveillance (Schwab 1982; Ho et al., 2013). 
CD30 is a transmembrane receptor which belongs to the TNFR 
superfamily. Interestingly, CD30 was found to be ectopically 
expressed on HRS cells in almost all HL cases (Schwab et al 1982; 
Nadali G et al, 1994). The corresponding ligand, CD30 ligand 
(CD30L), was found to be produced by activated T cells, stimulated 
monocytes, macrophages and eosinophils (Smith CA et al, 1993; 
Gattei et al, 1997). Expression of functional CD30L has also been 
observed on lymphocytes and granulocytes in HL affected lymph 
nodes (Pinto et al, 1996). In particular, CD30L in mast cells has been 
found to stimulate growth of HRS cells via CD30/CD30L interactions 
(Molin et al., 2001). Clinical studies, involving a humanized 
monoclonal antibody targeting CD30 known as Brentuximab vedotin, 
have shown excellent results in a phase II study of 102 patients with 
75% response rate and 34% complete remission in CD30-positive HL 
patients who have relapsed (Younes A et al., 2012). These results 
outlined the importance of CD30/CD30L interactions in treating HL. 
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 Secondly, the ability of HRS cells to survive and proliferate in the 
stroma of HL lesions which were overwhelmed by immune infiltrates 
implied the presence of possible effective immunosuppressive 
mechanisms. In perspective, the ectopic expression of CD137 on 
HRS cells contributed to the inhibition of T cell co-stimulation and 
supports the immune evasion employed by HRS cells in HL (Ho et al., 
2013). Association of CD137 and CD137L proteins on HRS cells, 
resulting in internalization of the CD137/CD137L complexes, 
effectively reduced costimulation of infiltrating T cells and evading 
immune surveillance. Inhibition of T cell co-stimulation was also found 
to be achieved by the trogocytic transfer of CD137 on HRS cells to 
neighbouring CD137L APCs, resulting in internalization of 
CD137/CD137L complexes and negatively impacting T cell 
costimulation (Ho et al., 2013). 
In this research, hepaCAM expression was screened in various cell 
lineages including HRS cell lines. Surprisingly, we made a 
serendipitous observation that the expression of hepaCAM was 
elevated in CD137-expressing HRS cell lines compared to CD137-
deficient cell lines. We noticed that CD137 expression upregulated 
the expression of hepaCAM and CD137 silencing engendered the 
downregulation of hepaCAM. However, in CD137-deficient cell lines, 
a low level of hepaCAM was observed. Therefore, there could be 
other factors affecting hepaCAM expression in HRS cells. 
 Affymetrix U95A oligonucleotide microarrays compromising of about 
12,000 human mRNAs were used to analyse the gene expression 
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 profile of the 4 HRS cell lines. The data sets were compared with 
normal B cell subsets (GC B cells, naïve and memory B cells), B cell 
malignancies (diffuse large cell lymphoma; DLCL), follicular 
lymphoma (FL), Burkitt lymphoma (BL), EBV-transformed peripheral 
leukemia (LCL) and B cell chronic lymphocytic leukemia (B-CLL). 
Unsupervised clustering shows that the 4 HRS cell lines are more 
similar to one another compared to other normal or malignant B cell. 
Therefore, it implies that the HRS cell lines represent a distinct group 
among the different B cell types analysed. In the 4 HRS cell lines, 27 
genes are specifically and consistently upregulated in HRS cells and 
45 genes are downregulated (Küppers R et al., 2003). Among the 
distinct named genes upregulated in HRS cells, two genes are well 
known for their expression in HRS cells such as actin-bundling protein 
Fascin and the chemokine TARC. Expression of TNF receptor family 
member RTANK and the mettaloproteinase TIMP1 by HRS cells have 
been described in other studies (Fiumara P et al., 2001).  HRS cell 
lines clustered as a distinct entity, irrespective of their B or T cell 
derivations and are derived from tumor types likely corresponding to 
transformed GC B cells. This raises the possibility that (opposed to 
most other lymphomas) HRS cells results in a specific and particular 
gene expression profile largely independent from their derivation of 
either B or T cells, but both B cell-derived and T cell-derived HRS 
cells undergo common transforming events resulting in an HRS cell-
typical gene expression signature (Küppers R et al., 2003). Therefore, 
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 the results obtained from the 4 selected HRS cell lines are possibly 
independent from genetic aberrations that may confound the data. 
However, the exact mechanism responsible for the elevation of 
hepaCAM expression by CD137 is still elusive.  
hepaCAM could possibly be regulated by CD137 signalling pathways. 
Members of the NF-κB pathway, such as c-Jun and c-Fos, may play a 
role in regulation of expression of hepaCAM. C-Jun and c-Fos have 
been found to have putative binding sites on hepaCAM enhancer 
regions. In addition, members of NF-κB such as RelA/p65 have been 
found to interact with STAT3, which is constitutively activated in HRS 
cells, to increase transcriptional activity (Sergei Grivennikov and 
Michael Karin., 2010). Regulation of hepaCAM could be explored by 
investigating the interactions between NF-κB and STAT3 as putative 
binding sites for STAT3 have been found on the enhancer regions of 
hepaCAM. 
Since TNFRs and CAMs are known to work in concert in tumor 
progression (Neumann B et al., 1996), the regulation of hepaCAM 
expression by CD137 in HRS cells may contribute to CD137-
mediated inactivation of T cells in HRS cells (Ho et al., 2013), tumor 
metastasis (Wai Wong C et al., 2012; Ugo Cavallaro et al., 2004) or 
enhanced recruitment of leukocytes to tumor sites (Palazon A et al., 




  5.2 Physical interactions between hepaCAM and CD137 in 
CD137-expressing HRS cells        
 
   Many adhesion molecules such as IgSF, selectins and integrins have 
been known to interact with members of the TNF family (Spiecker  M 
et al., 1998; Neumann B et al., 1996). Specifically, TNF has been 
known to induce expression and interaction with VCAM-1 and ICAM-1 
(Khachiqian LM et al., 1995). In the central nervous system, ICAM-1 
expression, which was found to be regulated by TNFR, play a role in 
immunological and inflammatory responses (Etienne-Manneville S et 
al., 1999).  
CD137 has been shown to be a binding partner hepaCAM in HRS 
cells and heterologous expression such as MCF-7 cell line. Co-
immunoprecipitation analyses showed that hepaCAM bound CD137 
in CD137-expressing HRS cells. The interaction was abolished when 
the cytoplasmic tail of hepaCAM was truncated in mutation analysis, 
suggesting that the cytoplasmic domain of hepaCAM is important for 
this association. Dimerization of extracellular domains of hepaCAM 
(Moh et al., 2005) may result in phosphorylation of cytoplasmic 
domains, which may trigger intrinsic catalytic activity of the receptor or 
serve as recruitment sites of downstream proteins (Plotnikov AN et al., 
1999). Enzymatic dephosphorylation of hepaCAM has revealed that 
the intracellular cytoplasmic domain of hepaCAM was phosphorylated 
with predicted potential serine/threonine and tyrosine kinase 
phosphorylation sites. Therefore, the potential sites of 
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 phosphorylation in the cytoplasmic domain may indicate an important 
role of hepaCAM cytoplasmic domain interacting with CD137 in signal 
transduction. In addition, sequence analyses revealed proline-rich 
regions with 6 SH3-domains (Moh et al., 2005). Adaptor proteins 
which contain SH3 domains may associate with the cytoplasmic 
domain of hepaCAM and induce intracellular signaling. However, the 
nature and presence of possible adaptor proteins involved in the 
interactions between hepaCAM and CD137 requires more exploration. 
Furthermore, the physical interactions between hepaCAM and CD137 
may serve to tighten adhesion of surrounding lymphocytes to HRS 
cells, prior to subsequent anergy of immune cells and release of 
survival signals from immune cells to HRS cells. 
5.3 Co-localisation of hepaCAM and CD137 on surface of 
CD137-expressing HRS cell lines influencing tumor stroma rich 
in immune infiltrates 
                                                                                                    
HRS cells have been known to be surrounded by a vast majority of 
reactive cells, including predominantly T lymphocytes, eosinophils, 
histiocytes, and plasma cells. Several mechanisms have been shown 
to be employed by HRS cells to attract these immune cells into the HL 
microenvironment, resulting in survival of HRS cells as well as escape 
from immune surveillance. 
T cells surrounding HRS cells appeared to be anergic and do not 
express certain co-stimulatory molecules such as CD4+CD26−T cells. 
An absence of mRNA induction for most cytokines indicates a 
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 functional limitation of the CD4+CD26− T cells, as shown in nodular 
sclerosis HL (Yue Ma et al., 2008). Presence of CD4+CD25+ Tregs in 
the HL infiltrating lymphocytes have also been reported (Marshall et 
al., 2004). In some studies, the prevalence of Treg to total CD4+ T 
cells were found to be significantly higher in breast (16.6%) and 
pancreas cancer (13.2%) patients, compared to normal patients  
(8.6%). As these data possibly indicated the possible suppressive role 
of Tregs in immune response against tumors (Liyanage UK et al., 
2002, Wolf AM et al., 2003), Tregs would be expected to exert local 
immunosuppressive effects to aid HRS cells in escape from immune 
surveillance and immune clearance (Yue Ma et al., 2008). 
Furthermore, T cells are attracted into HL lesions by chemokines 
such as T cell directed CC chemokine TARC in HRS cell lines. As 
expression of TARC has been reported constitutively in the thymus 
and in activated peripheral blood monocytes, TARC may play a role in 
T cell development in the thymus and in trafficking and activation of 
mature T cells (Imai T et al., 1996). Furthermore, TARC in HRS cells 
has been shown to bind to CCR4 in surrounding Th2-like lymphocytes, 
suggesting the possibility of TARC being responsible for the attraction 
of Th2 lymphocytes into the tissues involved by Hodgkin's lymphoma. 
In addition, the characteristic T cell rosetting around HRS cells was 
found to be related to cell-cell dependent pathways which include 
adhesion molecules presented by T cells and HRS cells. 
CD30/CD30L and CD40/CD40L are examples of membrane 
associated glycoproteins that act as adhesion molecules between T 
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 cells and HRS cells, as well as growth factors on HRS cells to 
stimulate growth and evade immune surveillance. Other adhesion 
molecules such as CD54/ICAM-1 have also been found to be up-
regulated in HRS cells to mediate interactions between T cells and 
HRS cells (Uchihara et al., 2006; Küppers R 2009).  
In perspective, CD137 has been found to be implicated in inactivation 
of T cells in the tumor microenvironment of HRS cells, thus enabling 
escape from immune surveillance (Ho et al., 2013) as described in 
earlier sections.  
CD137-dependent localisation of hepaCAM may be crucial in 
stabilising the complex on cell surfaces of HRS cells. In addition to 
interacting directly with each other as seen in Section 5.2, co-
localisation of both proteins is important for the interactions to be 
physiologically relevant. CD137-dependent localisation of hepaCAM 
on cell surface may indicate the possible roles of hepaCAM in 
CD137-mediated functions in Hodgkin Lymphoma. CD137-dependent 
expression and localization of hepaCAM on the cell surface may 
contribute to the attraction and adhesion of leukocytes to HRS cells to 
“tighten” interactions prior to inactivation of T cells in the tumor stroma. 
Like other adhesion molecules characterized in HRS cells (e.g. CD54, 
CD30/CD30L, CD40/CD40L), hepaCAM may also participate in 
adhesion of PBMCs to HRS cells for release of survival signals 
provided by the leukocytes to the tumor cells and/or releasing 
cytokines or chemokines resulting in an immunosuppressive 
environment.  
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 Furthermore, LTα has been shown to result in up-regulation of 
adhesion molecules such as ICAM-1, VCAM-1, E-selectin and 
hyaluronan in endothelial cells which was proposed to be important in 
recruitment of T cells in HL lesions (Höpken et al., 2014). hepaCAM 
expression by endothelial cells in HL lesions may also be explored to 
further understand the role of hepaCAM in leukocytes attraction and 
possible immune suppression.  
5.4 Adhesive and cell spreading properties of hepaCAM to 
fibronectin, a major component of the extracellular matrix 
                                                                                                                    
  Cell adhesion and cell spreading are important functions mediated by 
CAMs in cell growth, angiogenesis, metastasis and migration, 
between adjacent cells and components of the ECM (Gumbiner BM et 
al., 1996; Hynes et al., 1992; Mosher et al., 1992).  
hepaCAM has also been known to interact with fibronectin in breast 
cancer cell lines such as MCF-7 expressing hepaCAM (Moh MC et al., 
2008). Cell adhesion and spreading assays demonstrated that 
hepaCAM in HRS cells increased cell adhesion and cell spreading on 
fibronectin matrices. However, there may be other cognate fibronectin 
receptors on HRS cells hepaCAM blocking antibody did not 
completely abrogate adhesion of HRS cells to fibronectin matrices. 
5.5 hepaCAM-mediated adhesion of leukocytes to HRS cells  
Activated PBMCs were found to adhere to purified hepaCAM protein. 
Similarly, adhesion of HRS cells to activated PBMCs was found to be 
mediated by hepaCAM. Based on these preliminary results, it is 
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 possible that hepaCAM has potential binding partner/s in PBMCs. 
The possible hepaCAM binding partner/s in the activated PBMCs 
is/are still unknown and may require quantitative proteomics analysis 
of affinity-purified hepaCAM to identify the candidates for hepaCAM in 
activated PBMCs. Protein abundance determined by quantitative 
mass spectrometry will determine the possible binding partner/s of 
hepaCAM in activated PBMCs.  
CAMS have been known to be involved in adhesion of leukocytes to 
endothelial cells to aid in metastasis (Dustin et al., 1988; Sans E et al., 
2001) as well as adhesion of leukocytes to tumor cells (Uchihara et al., 
2006). The potential roles of hepaCAM in adhesion of leukocytes in 
HRS cells could be to aid in 1) subsequent inactivation of T cells by 
HRS cells and/or 2) induction of survival signals for HRS cell from 
leukocytes (Ho et al., 2013).  
CD137-regulated hepaCAM expression on HRS cells, which resulted 
in adhesion of leukocytes to HRS cells, may be to aid in the 
subsequent inactivation of T cells by internalisation of CD137/CD137L 
complexes (Ho et al., 2013). hepaCAM-mediated adhesion of 
leukocytes to HRS cells, preceding inactivation of leukocytes by 
CD137/CD137L internalization, may be utilised actively to evade 
immune surveillance. This would provide a possible explanation for 
the ability of HRS cells to evade immune surveillance despite the 
abundance of immune infiltrates being attracted to the 
microenvironment of HRS cells. 
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 As HRS cells are surrounded by a large number of reactive and 
inflammatory cells, the network of cytokines and chemokines 
produced by HRS cells and the surrounding cells allow evasion from 
immune surveillance (Steidl C. et al., 2011; Aldinucci D et al., 2010; 
Liu Y et al., 2014). hepaCAM-mediated adhesion of leukocytes to 
HRS cells may play a role in bringing immune cells closer to HRS 
cells in the HL microenvironment, where the myriad of survival signals 
released by CD40L-expressing T cells, CD30L+ mast cells and 
eosinophils, or by a proliferation-inducing ligand (APRIL)-producing 
neutrophils may aid in evasion of immune surveillance by HRS cells 
(Aldinucci D et al., 2010). Adhesion of leukocytes to HRS cells via 
ICAM-1 mediated pathways was found to provide survival signals 
from T cells to HRS cells (Küppers R, 2012). Possibly, the presence 
of hepaCAM on HRS cells may serve the same purpose of providing 
survival signals from neighbouring leukocytes to HRS cells. 
5.6     hepaCAM-mediated infiltration of PBMCs in HRS spheroids 
PBMCs have been known to infiltrate tumors in higher numbers 
compared to normal tissue in normal physiological conditions 
(Ahmadzadeh M et al., 2009; Okita K et al., 2005). In spite of the 
abundance of immune cells in the tumor microenvironment, the 
tumors were able to survive in the host. In melanomas, high levels of 
CD8+ T cells were observed to infiltrate the tumors and T cells were 
inactivated with up-regulation of PD1, and impairing the anti-tumor 
immune responses (Ahmadzadeh M et al., 2009). Furthermore, tumor 
infiltrating lymphocytes were found to possess poor immune 
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 responses due to the tumor microenvironment (Ichihara F et al., 
2003).  
hepaCAM-mediated infiltration of PBMCs in HRS spheroids was 
observed. These effects appeared to be inhibited by anti-hepaCAM 
blocking antibodies. This indicated the possible role of hepaCAM in 
attracting PBMCs to the HRS spheroids and subsequent infiltration 
into the spheroids. In addition, there could be other hepaCAM-
independent factors affecting the adhesion and infiltration of PBMCs 
in HRS spheroids, as adhesion and infiltration of PBMCs still occurred 
to a smaller extent when hepaCAM binding sites are blocked. 
The mechanisms concerning hepaCAM-mediated infiltration of 
PBMCs in the HRS spheroids remain to be elucidated. Infiltration of 
PBMCs in HRS spheroids may create a microenvironment to 
inactivate the lymphocytes, favour an immunosuppressive 
microenvironment and prevent proliferation of lymphocytes (Kolenko 
V et al., 1997; Mulder W.M. et al., 1997; Camp B.J et al., 1996; Gimmi 
C.D. et al., 1996; Bennett M.W. et al., 1998). 
Taken together, hepaCAM-mediated adhesion and attraction of 
PBMCs to HRS cells indicated that the physical association of HRS 
cells and PBMCs may play a role in CD137-mediated escape from 
immune surveillance. Consistent with the role of CAMs in HL, 
regulation of hepaCAM expression by CD137 in HRS cells may aid in 
inactivation of leukocytes mediated by CD137 (Ho et al., 2013) and/or 
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 providing survival signals to HRS cells from leukocytes (Kuppers R et 



















   CHAPTER 6 CONCLUSIONS 
Based on the results obtained from this study, it has been found that 
1) Expression and localisation of hepaCAM is CD137-dependent in 
HRS cell lines; 2) hepaCAM and CD137 associate with each other; 3) 
Cell adhesion and cell spreading of HRS cells on fibronectin are 
hepaCAM-mediated; 4) Adhesion and infiltration of leukocytes to HRS 
cell spheroids is hepaCAM-mediated. 
In concurrence with existing literature, this study supports the theory 
of the role of CAMs in adhesion and infiltration of leukocytes in HL 
(Küppers R et al., 2012). It provides insight into the possible roles of 
hepaCAM in adhesion of leukocytes prior to inactivation of T cells by 
CD137/CD137L (Ho et al., 2013) and the production of survival 
signals by leukocytes to HRS cells (Molin D et al., 2001). 
Future works would be needed to 1) Identify the possible binding 
partner/s of hepaCAM on HRS cells using quantitative proteomics 
analyses and mass spectrometry, 2) Determine possible transcription 
factors in CD137 signalling pathway which regulate hepaCAM 
expression in HRS cells, 3) Determine the nature of the binding 
partner/s of hepaCAM would provide a more detailed understanding 
of the role of hepaCAM in HRS cells, 4) Analysing hepaCAM and 
CD137 in HL patients’ tissues may further confirm the expression and 
localisation of hepaCAM, and its significance in HL, and 5) Eludicate 
possible crosstalks and interactions between hepaCAM and other cell 
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 adhesion molecules in HRS cells which may be beneficial in 
























Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley 
ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells 
infiltrating the tumor express high levels of PD-1 and are functionally 
impaired. Blood 2009 Aug 20;114(8):1537-44.  
Akiyama Y, Jung S, Salhia B, Lee S, Hubbard S, Taylor M, Mainprize 
T, Akaishi K, van Furth W, Rutka JT. Hyaluronate receptors mediating 
glioma cell migration and proliferation. J Neuro Oncol 2001 
Jun;53(2):115-27. 
Alaish SM, Yager D, Diegelmann RF, Cohen IK. Biology of fetal 
wound healing: hyaluronate receptor expression in fetal fibroblasts. J 
Pediatr Surg 1994 Aug;29(8):1040-3. 
Albelda S. M. and Buck, C. A. Integrins and other cell adhesion 
molecules. FASEB J 1990;4:2868-2880. 
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th 
edition. New York: Garland Science; 2002. Helper T Cells and 
Lymphocyte Activation. 
Aldinucci D., Gloghini, A., Pinto, A., De Filippi, R. and Carbone, A. 
The classical Hodgkin's lymphoma microenvironment and its role in 
promoting tumour growth and immune escape. J. Pathol 2010;221: 
248–263.  
Alho AM, Underhill CB. The hyaluronate receptor is preferentially 
expressed on proliferating epithelial cells. J Cell Biol 1989 
Apr;108(4):1557-65. 
Alitalo K. The lymphatic vasculature in disease. Nat Med 2011 Nov 
7;17(11):1371-80.  
Angst BD, Marcozzi C, Magee AI. The cadherin superfamily. J Cell 
Sci 2001 Feb;114(Pt 4):625-6 
Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-
CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and 
anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-9. 
Avi Ashkenazi and Vishva M. Dixit Death Receptors: Signaling and 
Modulation 1998;Science 281:1305 
Bastien D. Gomperts, Ijsbrand M. Kramer and Peter E.R. Tatham. 
Signal Transduction, Second Edition. Aug 19, 2009 
107
 Barclay AN. Membrane proteins with immunoglobulin-like domains--a 
master superfamily of interaction molecules. Semin Immunol 2003 
Aug;15(4):215-23.  
Bartlett NL et al., 2008; Bartlett NL, Younes A, Carabasi MH, et al. A 
phase 1 multidose study of SGN-30 immunotherapy in patients with 
refractory or recurrent CD30+ hematologic malignancies. Blood 
2008;111:1848-54.  
Basset C, Thiam F, Martino CD, Holton J, Clements JD, Kohli E. 
Cholera-like enterotoxins and Regulatory T cells. Toxins (Basel). 2010 
Jul;2(7):1774-95. 
Behrens J. Cadherins and catenins: role in signal transduction and 
tumor progression. Cancer Metastasis Rev 1999;18(1):15-30. 
Bennett MW, J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, 
J. K. Collins, F. Shanahan. The Fas counterattack in vivo: apoptotic 
depletion of tumor-infiltrating lymphocytes associated with Fas ligand 
expression by human esophageal carcinoma. Immunol J. 
1998;160(11):5669-75 
 
Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and 
immunodeficiency in persons with HIV/AIDS. Blood 108:3786–3791. 
Boll B, Hansen H, Heuck F, et al. The fully human anti-CD30 antibody 
5F11 activates NF-{kappa}B and sensitizeslymphoma cells to 
bortezomib-induced apoptosis. Blood 2006;106:1839-42. 
Boor P.K. Ilja, de Groot K., Mejaski-Bosnjak V., Brenner C., van der 
Knaap M.S., Scheper G.C., Pronk J.C. Megalencephalic 
leukoencephalopathy with subcortical cysts: An update and extended 
mutation analysis of MLC1. Hum. Mutat. 2006;27:505–512. 
Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte 
therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 
2004;200:1623-33. 
Borchmann P, Schnell R, Engert A. Immunotherapy of Hodgkin's 
lymphoma. Haematol Suppl. Eur J. 2005:159-65. 
Bräuninger A., M.L. Hansmann, J.G. Strickler, R. Dummer, G. Burg, K. 
Rajewsky, et al. Identification of common germinal-center B-cell 
precursors in two patients with both Hodgkin's disease and non-
Hodgkin's lymphoma The New England Journal of Medicine, 
1999;340:1239–1247 
Brignone M. S., Lanciotti A., Macioce P., Macchia G., Gaetani M., 
Aloisi F., et al. The beta1 subunit of the Na,K-ATPase pump interacts 
108
 with megalencephalic leukoencephalopathy with subcortical cysts 
protein 1 in brain astrocytes: new insights into MLC pathogenesis, 
Hum. Mol. Gen. 2011;20:90–103 
Brignone MS, Lanciotti A, Camerini S, et al. MLC1 protein: a likely link 
between leukodystrophies and brain channelopathies. Frontiers in 
Cellular Neuroscience. 2015;9:66. 
Bugiani M, Moroni I, Bizzi A, Nardocci N, Bettecken T, Gärtner J, 
Uziel G Consciousness disturbances in megalencephalic 
leukoencephalopathy with subcortical cysts. Neuropediatrics 2003 
Aug;34(4):211-4 
Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of 
paxillin and pp125FAK accompanies cell adhesion to extracellular 
matrix: a role in cytoskeletal assembly. J Cell Biol. 1992 
Nov;119(4):893-903. 
Cambier J.C., Stephen B. Gauld, Kevin T. Merrell & Barbara J. Vilen 
B-cell anergy: from transgenic models to naturally occurring anergic B 
cells? Nature Reviews Immunology Aug 2007:7:633-643 
Camp B.J. et al. In situ cytokine production by breast cancer tumor-
infiltrating lymphocytes. Ann Surg Oncol. 1996;3(2):176-84  
Capdevila-Nortes X, López-Hernández T, Apaja PM, López de 
Heredia M, Sirisi S, Callejo G, Arnedo T, Nunes V, Lukacs GL, Gasull 
X, Estévez R Insights into MLC pathogenesis: GlialCAM is an MLC1 
chaperone required for proper activation of volume-regulated anion 
currents. Hum Mol Genet. 2013 Nov 1; 22(21):4405-16. 
 
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. 
Report of the Committee on Hodgkin's Disease Staging Classification 
Cancer Res. 1971;31(11):1860 
Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins 
and Ig-CAMs in cancer. Nature Reviews Cancer 2004 Feb;4:118-132  
Cerveny CG, Law CL, McCormick RS, et al. Signaling via the anti-
CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to 
conventional chemotherapeutics. Leukemia 2005;19:1648-55. 
Chan F.K.M., Chun H.J., Zheng L.X., Siegel R.M., Bui K.L., Leonardo 
M.J. A domain in TNF receptors that mediates ligand-independent 
receptor assembly and  signaling. Science. 2000;288:2351–2354 
109
 Chang ET, Smedby KE, Hjalgrim H, Porwit-MacDonald A, Roos G, 
Glimelius B, Adami HO. Family history of hematopoietic malignancy 
and risk of lymphoma J Natl Cancer Inst. 2005 Oct 5;97(19):1466-74.  
Chen WY, Abatangelo G. Functions of hyaluronan in wound repair. 
Wound Repair Regen 1999 Mar-Apr;7(2):79-89. 
Choi I, Lee S, Hong YK. The new era of the lymphatic system: no 
longer secondary to the blood vascular system. Cold Spring Harb 
Perspect Med 2012 Apr;2(4):a006445.  
Cotran RS, Mayadas-Norton T. Endothelial adhesion molecules in 
health and disease. Pathol Biol (Paris) 1998 Mar;46(3):164-70. 
Couffinhal T, Cecile Duplaa, Laurence Labat, Jean-Marie Daniel 
Lamaziere, Catherine Moreau, Olga Printseva, and Jacques Bonnet. 
Tumor necrosis factor-alpha stimulates ICAM-1 expression in human 
vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and 
Vascular Biology 1993; 13: 407-414 
Cueni LN, Chen L, Zhang H, Marino D, Huggenberger R, Alitalo A, 
Bianchi R, Detmar M. Podoplanin-Fc reduces lymphatic vessel 
formation in vitro and in vivo and causes disseminated intravascular 
coagulation when transgenically expressed in the skin. Blood 2010 
Nov 18;116(20):4376-84.  
Davies FE, Raje N, Hideshima T, et al. Thalidomide and 
immunomodulatory derivatives augment natural killer cell cytotoxicity 
in multiple myeloma. Blood 2001;98:210-6. 
Davies M, Arumugam PJ, Shah VI, et al. The clinical significance of 
lymph node micrometastasis in stage I and stage II colorectal cancer. 
Clin Transl Oncol 2008;10(3):175-179 
Depienne C, Bugiani M, Dupuits C, Galanaud D, Touitou V, Postma N, 
van Berkel C, Polder E, Tollard E, Darios F, et al. Brain white matter 
oedema due to ClC-2 chloride channel deficiency: an observational 
analytical study. Lancet Neurol. 2013;12:659–668 
Duarri A., Teijido O., Lopez-Hernandez T., Scheper G.C., Barriere H., 
Boor I., Aguado F., Zorzano A., Palacin M., Martinez A., et al. 
Molecular pathogenesis of megalencephalic leukoencephalopathy 
with subcortical cysts: mutations in MLC1 cause folding defects. Hum. 
Mol. Genet. 2008;17:3728-3739. 
110
 Duarri A, de Heredia ML, Capdevila-Nortes X, et al. Knockdown of 
MLC1 in primary astrocytes causes cell vacuolation: a MLC disease 
cell model. Neurobiology of disease. 2011;43(1):10.1016 
Dustin, M.L., and Springer, T.A. Lymphocyte function associated 
antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 
(ICAM-1) is one of at least three mechanisms for lymphocyte 
adhesion to cultured endothelial cells. J. Cell. Biol 1988;107, 321–331. 
Ebnet K, Suzuki A, Ohno S, Vestweber D. Junctional adhesion 
molecules (JAMs): more molecules with dual functions? J Cell Sci 
2004 Jan 1;117(Pt 1):19-29. 
Edelman GM. Cell adhesion molecules. Science 1983 Feb 
4;219(4584):450-7. 
Engert A, Diehl V, Schnell R, et al. A phase-I study of an anti-CD25 
ricin A-chain immunotoxin (RFT5-SMPTdgA) in patients with 
refractory Hodgkin's lymphoma. Blood 1997;89:403-10. 
Etienne-Manneville S, N. Chaverot, A. D. Strosberg, P. O. Couraud. 
ICAM-1-coupled signaling pathways in astrocytes converge to cyclic 
AMP response element-binding protein phosphorylation and TNF-
alpha secretion. J Immunol. 1999 July 15; 163(2): 668–674. 
Falini B, Bolognesi A, Flenghi L, et al. Response of refractory 
Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 
1992;339:1195-1196. 
Favre-Kontula L., Rolland A., Boschert U. GlialCAM, an 
immunoglobulin-like cell adhesion molecule is expressed in glial cells 
of the central nervous system. Glia. 2008;56:633–645. 
Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O'Brien S, Lerner S, 
Beran M, Kantarjian HM, Freireich EJ, Albitar M.  High levels of 
vascular endothelial growth factor receptor-2 correlate with shortened 




Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, 
Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, 
Albitar M. The clinical significance of tumor necrosis factor-alpha 
plasma level in patients having chronic lymphocytic leukemia. Blood 
2002 Aug 15;100(4):1215-9. 
 
Fiumara P, et al. Functional expression of receptor activator of 




 García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. 
Role of tumor necrosis factor-alpha and its receptors in human benign 
breast lesions and tumors (in situ and infiltrative). Cancer Sci 2006 
Oct;97(10):1044-9. 
 
Gattei V1, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, 
Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Gruss HJ, 
Carbone A, Pinto A. CD30 ligand is frequently expressed in human 
hematopoietic malignancies of myeloid and lymphoid origin. Blood. 
1997 Mar 15;89(6):2048-59. 
 
Giaccia AJ, Erler JT. The cellular microenvironment and metastases. 
Abeloff’s Clinical Oncology 4th ed. 2008 Philadelphia: Churchill 
Livingstone:33-47 
Gimmi C.D. et al. Breast cancer-associated antigen, DF3/MUC1, 
induces apoptosis of activated human T cells. Nat 
Med.1996;2(12):1367-70 
Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, 
Greenberg NM, Elgavish A, Languino LR. beta1A integrin expression 
is required for type 1 insulin-like growth factor receptor mitogenic and 
transforming activities and localization to focal contacts. Cancer Res 
2005 Aug 1;65(15):6692-700. 
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM Incidence of 
cancers in people with HIV/AIDS compared with immunosuppressed 
transplant recipients: a meta-analysis. Lancet 2007;370:59-67 
Gumbiner BM Cell adhesion: the molecular basis of tissue 
architecture and morphogenesis. Cell 1996 February 9; 84(3): 345–
357. 
Hardwick, C, Hoare, K, Owens, R et al. J Cell Biol. Molecular cloning 
of a novel hyaluronan receptor that mediates tumor cell motility 
[published erratum appears in J Cell Biol 118:753, 1992]. 1992;117, 
1343–1350, 
Harpaz Y, Chothia C. Many of the immunoglobulin superfamily 
domains in cell adhesion molecules and surface receptors belong to a 
new structural set which is close to that containing variable domains. 
J Mol Biol 1994 May 13;238(4):528-39. 
Harrington LE, Janowski KM, Oliver JR, Zajac AJ, Weaver CT. 
Memory CD4 T cells emerge from effector T-cell progenitors. Nature 
2008 Mar 20;452(7185):356-60 
112
 Hartmann F, Renner C, Jung W, et al. Treatment of refractory 
Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 
1997;89:2042-7. 
Hay, E. D., editor. Cell Biology of Extracellular Matrix. 1981; Plenum 
Publishing Corp., New York. 417 pp. 
Herbst H, Dallenbach F, Hummel M, Niedobitek G. Pileri S, Muller-
Lantzsch N, Stein H: Epstein-Barr virus latent membrane protein 
expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci 
USA 1991;88:4766 
Ho WT, Wan Lu Pang, Siew Meng Chong, Antonio Castella, Suhail 
Al-Salam, Teng Ee Tan, Mei Chung Moh, Liang Kai Koh, Shu Uin 
Gan, Cheong Kin Cheng, and Herbert Schwarz. Expression of CD137 
on Hodgkin and Reed-Sternberg Cells Inhibits T cell Activation by 
Eliminating CD137 Ligand Expression. Cancer Res 2013 Jan 
15;73(2):652-61.  
Hoegg-Beiler M.B., Sirisi S., Jentsch T.J. Disrupting MLC1 and 
GlialCAM and ClC-2 interactions in leukodystrophy entails glial 
chloride channel dysfunction. Nat. Commun. 2014;5:3475. 
Höpken Uta E.  Lymphotoxin-α keeps the gate open for T-cell 
infiltration in cHL. Blood 2014;124:2897-2898; 
Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by 
naturally arising regulatory CD4+ T cells. Adv Immunol 2003;81:331-
71. Review 
Horie R, Higashihara M, Watanabe T. Hodgkin's lymphoma and 
CD30 signal transduction. Int J Hematol 2003 Jan;77(1):37-47. 
Hsu H., Xiong J., Goeddel D. V. (1995) The TNF receptor 1-
associated protein TRADD signals cell death and NF-kappa B 
activation. Cell 81:495–504. 
Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. 
Int J Biochem Cell Biol 2009 Feb;41(2):349-69.  
Humphries M.J. Integrin structure. Biochem Soc Trans 
2000;28(4):311-39. 
Hynes, R.O. Fibronectins. Springer-Verlag, New York 1990;546 pp. 
Ichihara F, Koji Kono, Akihiro Takahashi, Hiromichi Kawaida, 
Hidemitsu Sugai, Hideki Fujii Increased populations of regulatory T 
cells in peripheral blood and tumor-infiltrating lymphocytes in patients 
113
 with gastric and esophageal cancers. Clin Cancer Res. 2003 October 
1; 9(12): 4404–4408. 
 
Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O. 
Molecular cloning of a novel T cell-directed CC chemokine expressed 
in thymus by signal sequence trap using Epstein-Barr virus vector. J 
Biol Chem. 1996 Aug 30;271(35):21514-21. 
 
Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int J 
Biochem Cell Biol 2002 Jul;34(7):718-21. 
Jarrett AF, Armstrong AA, Alexander E. Epidemiology of EBV and 
Hodgkin's lymphoma. Ann Oncol. 1996;7 Suppl 4:5-10. 
Jang YN, Jung YS, Lee SH, Moon CH, Kim CH, Baik EJ. Calpain-
mediated N-cadherin proteolytic processing in brain injury. J Neurosci 
2009 May 6;29(18):5974-84.  
Janeway CA Jr. How the immune system protects the host from 
infection. Microbes Infect 2001 Nov;3(13):1167-71. Review 
Juliano RL. Signal transduction by cell adhesion receptors and the 
cytoskeleton: functions of integrins, cadherins, selectins, and 
immunoglobulin-superfamily members. Annu Rev Pharmacol Toxicol 
2002;42:283-323. 
Kanzler H., Küppers R., Hansmann M.L., Rajewsky K. Hodgkin and 
Reed–Sternberg cells in Hodgkin's disease represent the outgrowth 
of a dominant tumor clone derived from (crippled) germinal center B 
cells Journal of Experimental Medicine, 1996;184:1495–1505 
 
Kelly CP, O'Keane JC, Orellana J, Schroy PC 3rd, Yang S, LaMont 
JT, Brady HR.  Human colon cancer cells express ICAM-1 in vivo and 
support LFA-1-dependent lymphocyte adhesion in vitro. Am J Physiol 
1992 Dec;263(6 Pt 1):G864-70. 
 
Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact 
inhibition of proliferation through Hippo signaling-pathway 
components. Proc Natl Acad Sci U S A 2011 Jul 19;108(29):11930-5.  
Kim SH, Jeremy E Turnbull, and Scott E Guimond. Extracellular 
matrix and cell signalling – the dynamic cooperation of integrin, 
proteoglycan and growth factor receptor. J Endocrinol 2011 
May;209(2): 139–151. 
114
 Kishimoto, T.K., Larson, R.S., Corbi, A.L., Dustin, M.L., Staunton, D. 
E., and Springer, T.A. The leukocyte integrins: LFA-1, Mac-1, and 
pl50. Adv. Immunol 1989;95. 46, 149–182. 
Klimm B, Schnell R, Diehl V, Engert A. Current treatment and 
immunotherapy of Hodgkin's lymphoma. Haematologica 
2005;90:1680-92. 
Kolenko V. et al. Tumor-induced suppression of T lymphocyte 
proliferation coincides with inhibition of Jak3 expression and IL-2 
receptor signaling: role of soluble products from human renal cell 
carcinomas. Immunol J. 1997;159(6):3057-67 
Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms 
versus contributions by the tumor microenvironment.  Cell Mol Life Sci 
2006 Feb;63(4):449-68. Review 
Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, 
Burakoff SJ. The functional significance, distribution, and structure of 
LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-
target interactions. J Immunol 1983 Aug;131(2):611-6. 
Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin 
and Reed-Sternberg cells picked from histological sections show 
clonal immunoglobulin gene rearrangements and appear to be 
derived from B cells at various stages of development. Proceedings of 
the National Academy of Sciences of the United States of America. 
1994;91(23):10962-10966. 
Küppers R, Klein U, Schwering I, et al. Identification of Hodgkin and 
Reed-Sternberg cell-specific genes by gene expression profiling. 
Journal of Clinical Investigation. 2003;111(4):529-537. 
doi:10.1172/JCI200316624. 
Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am 
Soc Hematol Educ Program. 2009:491-6.  
Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin 
Invest. 2012 Oct;122(10):3439-47.  
Lanciotti A, Brignone MS, Bertini E, Petrucci TC, Aloisi F, Ambrosini E 
Astrocytes: Emerging stars in leukodystrophy pathogenesis Transl 
Neurosci. 2013 Jun 1;4(2) 
Leegwater P.A., Yuan B.Q., van der Steen J., Mulders J., Konst A.A., 
Boor P.K., Mejaski-Bosnjak V., van der Maarel S.M., Frants R.R., 
Oudejans C.B., et al. Mutations of MLC1 (KIAA0027), encoding a 
putative membrane protein, cause megalencephalic 
115
 leukoencephalopathy with subcortical cysts. Am. J. Hum. Genet. 
2001;68:831-838. 
Ley K. The role of selectins in inflammation and disease. Trends Mol 
Med 2003 Jun;9(6):263-8. 
Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee 
convened to discuss the evaluation and staging of patients with 
Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov. 
7(11):1630-6. 
Liu Y, Ahmad Sattarzadeh, Arjan Diepstra, Lydia Visser, Anke van 
den Berg. The microenvironment in classical Hodgkin lymphoma: An 
actively shaped and essential tumor component. Semin Cancer Biol. 
2014 February; 24: 15–22.  
 
Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T 
cells is increased in peripheral blood and tumor microenvironment of 
patients with pancreas or breast adenocarcinoma. J Immunol 
2002;169:2756–2761. 
 
López-Hernández T., Ridder M.C., Montolio M., Capdevila-Nortes X., 
Polder E., Sirisi S., Duarri A., Schulte U., Fakler B., Nunes V. Mutant 
GlialCAM causes megalencephalic leukoencephalopathy with 
subcortical cysts, benign familial macrocephaly, and macrocephaly 
with retardation and autism. Am. J. Hum. Genet. 2011;88:422–432.  
 
López-Hernández T., Sirisi S., Capdevila-Nortes X., Montolio M., 
Fernández-Dueñas V., Scheper G.C., van der Knaap M.S., Casquero 
P., Ciruela F., Ferrer I. Molecular mechanisms of MLC1 and 
GLIALCAM mutations in megalencephalic leukoencephalopathy with 
subcortical cysts. Hum. Mol. Genet. 2011;20:3266–3277. 
 
Thomas M. Mack, M.D., Wendy Cozen, D.O., Darryl K. Shibata, M.D., 
Lawrence M. Weiss, M.D., Bharat N. Nathwani, M.D., Antonio M. 
Hernandez, M.D., Clive R. Taylor, M.D., Ann S. Hamilton, Ph.D., 
Dennis M. Deapen, Dr.P.H., and Edward B. Rappaport, M.P.H. 
Concordance for Hodgkin's Disease in Identical Twins Suggesting 
Genetic Susceptibility to the Young-Adult Form of the Disease 
N Engl J Med 1995; 332:413-419 
 
Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive 
regulatory T cells are abundant in the reactive lymphocytes of 
Hodgkin lymphoma. Blood 2004;103:1755–1762. 
Mauri Claudia, Bosma A. Immune regulatory function of B cells. Rev 
Immunol 2012;30:221-41. Epub 2012 Jan 3. Review 
116
 McDuffie HH, Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA. 
Clustering of cancer among families of cases with Hodgkin 
Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma 
(NHL), Soft Tissue Sarcoma (STS) and control subjects. BMC Cancer. 
2009;9:70. 
Medeiros LJ, Greiner TC. Hodgkin's disease Cancer 1995 Jan 1;75(1 
Suppl):357-69.  
Melero I, Murillo O, Dubrot J, Hervás-Stubbs S, Perez-Gracia 
JL.  Multi-layered action mechanisms of CD137 (4-1BB)-targeted 
immunotherapies. Trends Pharmacol Sci 2008 Aug;29(8):383-90. 
  
Michalaki V et al., 2004; Michalaki V, Syrigos K, Charles P, Waxman 
J. Br Serum levels of IL-6 and TNF-alpha correlate with 
clinicopathological features and patient survival in patients with 
prostate cancer. J Cancer 2004 Jun 14;90(12):2312-6. 
 
Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, 
Eidelstein Y, Afik R, Antebi YE, Dustin ML, Reisner Y. CTLs respond 
with activation and granule secretion when serving as targets for T-
cell recognition. Blood 2011 Jan 20;117(3):1042-52 
Minn AJ, Massagué J. Invasion and metastasis. In DeVita VT, 
Lawrence TS, Rosenberg SA (Eds) Cancer Principles and Practice of 
Oncology 9th ed. New York: Lippincott Williams & Wilkins 2011;113-
127 
Moh MC, Chunli Zhang, Chunli Luo, Lay Hoon Lee and Shali Shen. 
Structural and Functional Analyses of a Novel Ig-like Cell Adhesion 
Molecule, hepaCAM, in the Human Breast Carcinoma MCF7 Cells. 
The Journal of Biological Chemistry 2005 July; 280, 27366-27374. 
 
Moh MC, Zhang T, Lee LH, Shen S. Expression of hepaCAM is 
downregulated in cancers and induces senescence-like growth arrest 
via a p53/p21-dependent pathway in human breast cancer cells. 
Carcinogenesis 2008 Dec;29(12):2298-305.   
Moh MC, Shen S. The roles of cell adhesion molecules in tumor 
suppression and cell migration: a new paradox. Cell Adh Migr 2009 
Oct-Dec;3(4):334-6. Epub 2009 Oct 12. 
 
Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson 
K, Sundström C, Enblad G, Nilsson G. Mast cells express functional 
CD30 ligand and are the predominant CD30L-positive cells in 
Hodgkin's disease. Br J Haematol. 2001 Sep;114(3):616-23.  
Mosher DF, J Sottile, C Wu, J.A McDonald Assembly of extracellular 
matrix. Curr. Opin. Cell Biol 1992;4, pp. 810–818 
117
 Mulder W.M. et al. cell receptor-zeta T and granzyme B expression in 
mononuclear cell infiltrates in normal colon mucosa and colon 
carcinoma. Gut. 1997;40(1):113-9 
Nadali, G., Vinante, F., Ambrosetti, A., Todeschini, G., Veneri, D., 
Zanotti, R., Meneghini, V., Ricetti, M.M., Vassanelli, A. Serum levels 
of soluble CD30 are elevated in the majority of untreated patients with 
Hodgkin's disease and correlate with clinical features and prognosis. 
Journal of Clinical Oncology 1994;12:793–797. 
Nakayamada S, Takahashi H, Kanno Y, O’Shea JJ. Helper T cell 
diversity and plasticity. Current Opinion in Immunology 
2012;24(3):297-302.  
Nermut MV, Green NM, Eason P, Yamada SS, Yamada KM. Electron 
microscopy and structural model of human fibronectin receptor. 
EMBO J 1988 Dec 20;7(13):4093-9. 
Neumann B, Machleidt T, Lifka A, Pfeffer K, Vestweber D, Mak TW, 
Holzmann B, Krönke M. Crucial role of 55-kilodalton TNF receptor in 
TNF-induced adhesion molecule expression and leukocyte organ 
infiltration. J Immunol 1996 Feb 15;156(4):1587-93. 
Okita K, Furuhata T, Kimura Y, Kawakami M, Yamaguchi K, Tsuruma 
T, Zembutsu H, Hirata K. The interplay between gastric cancer cell 
lines and PBMCs mediated by the CC chemokine RANTES plays an 
important role in tumor progression. J Exp Clin Cancer Res 2005 
Sep;24(3):439-46. 
Olberding JE, Thouless MD, Arruda EM, Garikipati K. The non-
equilibrium thermodynamics and kinetics of focal adhesion dynamics. 
PLoS One 2010 Aug 18;5(8):e12043.  
Osborn, L., Hession, C., Tizard, R., Vassallo, C., Luhowskyj, S., 
ChiRosso, G. and Lobb, R. Direct expression cloning of vascular cell 
adhesion molecule 1, a cytokine-induced endothelial protein that 
binds to lymphocytes. Cell 1989;59, 1203-1211. 
Palazón A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, 
Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa 
MC, Ochoa-Callejero L, Martínez A, Luque A, Dinchuk J, Rouzaut A, 
Jure-Kunkel M, Melero I. Agonist anti-CD137 mAb act on tumor 
endothelial cells to enhance recruitment of activated T lymphocytes. 
Cancer Res 2011 Feb 1;71(3):801-11 
118
 Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS: Expression of 
Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s 
disease. Lancet 1991;337:320 
Paschos KA, N. Bird. The intervention of immunoglobulin superfamily 
cell adhesion molecules in the progression of colorectal cancer and 
liver metastasis. Annals of Gastroenterology 2009. 22(2):82-89 
Parham P. Immunogenetics of killer cell immunoglobulin-like 
receptors. Mol Immunol. 2005 Feb;42(4):459-62. 
Patla I, Volberg T, Elad N, Hirschfeld-Warneken V, Grashoff C, 
Fässler R, Spatz JP, Geiger B, Medalia O. Dissecting the molecular 
architecture of integrin adhesion sites by cryo-electron tomography. 
Nat Cell Biol 2010 Sep;12(9):909-15.  
Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural 
basis for FGF receptor dimerization and activation. Cell. 1999 Sep 
3;98(5):641-50. 
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, 
Oshima M, Fujii C, Mukaida N.  Blocking TNF-alpha in mice reduces 
colorectal carcinogenesis associated with chronic colitis. J Clin Invest 
2008 Feb;118(2):560-70.  
Pu Xia, Jennifer R. Gamble, Kerry-Anne Rye, LiJun Wang, Charles S. 
T. Hll, Peter Cockerill, Yeesim Khew-Goodall, Andrew G. Bert, Philip 
J. Barter, And Mathew A. Vadas, Tumor necrosis factor-a induces 
adhesion molecule expression through the sphingosine kinase 
pathway Proc. Natl. Acad. Sci. USA. Cell Biology 1998; Vol. 95, pp. 
14196–14201  
 
Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to 
Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 
2005;105:4553 
Riveline D, Zamir E, Balaban NQ, Schwarz US, Ishizaki T, Narumiya 
S, Kam Z, Geiger B, Bershadsky AD. Focal contacts as 
mechanosensors: externally applied local mechanical force induces 
growth of focal contacts by an mDia1-dependent and ROCK-
independent mechanism. J Cell Biol 2001 Jun;153(6):1175-86. 
Sakaguchi S. Naturally arising CD4+ regulatory t cells for 
immunologic self-tolerance and negative control of immune 
responses. Annu Rev Immunol 2004;22:531-62. Review 
Sans E, Delachanal E, Duperray A. Analysis of the roles of ICAM-1 in 
neutrophil transmigration using a reconstituted mammalian cell 
119
 expression model: implication of ICAM-1 cytoplasmic domain and 
Rho-dependent signaling pathway. J Immunol. 2001 Jan 
1;166(1):544-51. 
Schwab, U., Stein, H., Gerdes, J., Lemke, H., Kirchner, H., Schaadt, 
M., Diehl, V. Production of a monoclonal antibody specific for Hodgkin 
and Sternberg-Reed cells of Hodgkin's disease and a subset of 
normal lymphoid cells. Nature 1982; 299:65–67. 
Schwarz BA, Bhandoola A. Trafficking from the bone marrow to the 
thymus: a prerequisite for thymopoiesis. Immunol Rev 2006 
Feb;209:47-57. Review 
Schwarz, H., Biological activities of reverse signal transduction 
through CD137 ligand. J. Leukoc. Biol. 2005. 77: 281–286. 
Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, 
Shealy DJ, Balkwill FR. An anti-tumor necrosis factor-alpha antibody 
inhibits the development of experimental skin tumors. Mol Cancer 
Ther 2003 May;2(5):445-51. 
 
Sergei Grivennikov and Michael Karin Dangerous liaisons: STAT3 
and NF-κB collaboration and crosstalk in cancer. Cytokine Growth 
Factor Rev. 2010 February; 21(1): 11–19. 
 
Shayan R, Achen MG, Stacker SA. Carcinogenesis. Lymphatic 
vessels in cancer metastasis: bridging the gaps. Journal of Cellular 
and Molecular Medicine 2006 Sep;27(9):1729-38. Epub 2006 Apr 5. 
Review 
 
Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-
dependent cellular cytotoxicity in tumor immunotherapy with 
therapeutic antibodies. Front Immunol. 2013 Mar 27;4:76. 
 
Singhal B. S., Gursahani R. D., Udani V. P., Biniwale A. A. 
Megalencephalic leukodystrophy in an Asian Indian ethnic group. 
Pediatr. Neurol. 1996 14 291–296 
 
Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, 
Savani RC, Kumar S. Hyaluronan-mediated angiogenesis in vascular 
disease: uncovering RHAMM and CD44 receptor signaling pathways. 
Matrix Biol 2007 Jan;26(1):58-68. Epub 2006 Sep 19. 
Smith CA1, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, 
Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, et al. CD30 
antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand 
defines an emerging family of cytokines with homology to TNF. Cell. 
1993 Jul 2;73(7):1349-60. 
120
 Song, X., Wang, Y., Du, H., Fan, Y., Yang, X., Wang, X., Wu, X. and 
Luo, C. Overexpression of HepaCAM inhibits cell viability and motility 
through suppressing nucleus translocation of androgen receptor and 
ERK signaling in prostate cancer. Prostate 2014;74: 1023–1033.  
Spiecker M, Harald Darius, Katharina Kaboth, Felix Hübner, and 
James K. Liao. Differential regulation of endothelial cell adhesion 
molecule expression by nitric oxide donors and antioxidants. J Leukoc 
Biol 1998 Jun;63(6):732-9. 
Springer, TA, Dustin, ML, Kishimoto, TK, Marlin, SD. The lymphocyte 
function-associated LFA-1, CD-2, and LFA-3 molecules: cell adhesion 
receptors of the immune system. Annu Rev Immunol 1987;5: 223–
252 
Steidl C, Joseph M. Connors, Randy D. Gascoyne. Molecular 
pathogenesis of Hodgkin's lymphoma: increasing evidence of 
the importance of the microenvironment. J Clin Oncol 2011 May 
10; 29(14): 1812–1826. 
 
Takeichi M. Cadherins: a molecular family important in selective cell-
cell adhesion. Annu Rev Biochem 1990;59:237-52. 
Teijido O., Martinez A., Pusch M., Zorzano A., Soriano E., Del Rio 
J.A., Palacin M., Estevez R. Localization and functional analyses of 
the MLC1 protein involved in megalencephalic leukoencephalopathy 
with subcortical cysts. Hum. Mol. Genet. 2004;13:2581-2594. 
Topcu M, Saatci I, Topcuoglu MA, Kose G, Kunak B Megalencephaly 
and leukodystrophy with mild clinical course: a report on 12 new 
cases. Brain Dev. 1998 Apr;20(3):142-53. 
Uchihara, J.-N., Matsuda, T., Okudaira, T., Ishikawa, C., Masuda, M., 
Horie, R., Watanabe, T., Ohta, T., Takasu, N. and Mori, N. Retracted: 
Transactivation of the ICAM-1 gene by CD30 in Hodgkin's lymphoma. 
Int. J. Cancer. 2006;118:1098–1107. 
van der Knaap MS1, Barth PG, Stroink H, van Nieuwenhuizen O, Arts 
WF, Hoogenraad F, Valk J. Leukoencephalopathy with swelling and a 
discrepantly mild clinical course in eight children. Ann Neurol. 1995 
Mar;37(3):324-34. 
van der Knaap, M. S., Barth, P. G., Vrensen, G. F., Valk, J. 
Histopathology of an infantile-onset spongiform leukoencephalopathy 
with a discrepantly mild clinical course. Acta Neuropath. 1996;92: 
206-212. 
121
 van der Knaap MS, Scheper GC. Megalencephalic 
Leukoencephalopathy with Subcortical Cysts. 2011 Aug 11 Seattle 
(WA): University of Washington, Seattle; 1993-2016. 
van der Knaap MS1, Boor I, Estévez R. Megalencephalic 
leukoencephalopathy with subcortical cysts: chronic white matter 
oedema due to a defect in brain ion and water homoeostasis. Lancet 
Neurol. 2012 Nov;11(11):973-85. doi: 10.1016/S1474-
4422(12)70192-8. 
Wai Wong C, Dye DE, Coombe DR. The role of immunoglobulin 
superfamily cell adhesion molecules in cancer metastasis. Int J Cell 
Biol 2012;2012:340296.  
Wang Q, Luo C, Wu X, Du H, Song X, Fan Y.  hepaCAM and p-
mTOR closely correlate in bladder transitional cell carcinoma and 
hepaCAM expression inhibits proliferation via an AMPK/mTOR 
dependent pathway in human bladder cancer cells. J Urol 2013 
Nov;190(5):1912-8. Epub 2013 May 10. 
 
Weiss, L.M., Chan, J.K.C., MacLennan, K., and Warnke, R.A. 1999. 
Pathology of classical Hodgkin’s disease. In Hodgkin’s disease. P.M. 
Mauch, J.O. Armitage, V. Diehl, R.T. Hoppe, L.M. Weiss, editors. 
Lippencott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 101–
120. 
 
Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia 
R, von Andrian UH, Ahmed R. Nat Immunol 2003 Mar;4(3):225-34. 
Epub 2003 Feb 3 
Willard-Mack CL Normal structure, function, and histology of lymph 
nodes. Toxicol Pathol. 2006;34(5):409-24 
Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF. J 
Lineage relationship and protective immunity of memory CD8 T cell 
subsets. Immunol 2005 Nov 1;175(9):5895-903 
Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the 
peripheral blood of cancer patients. Clin Cancer Res 2003;9:606–612. 
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage 
KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-
Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy 
DA, Sievers EL, Chen R. Results of a pivotal phase II study of 
brentuximab vedotin for patients with relapsed or refractory Hodgkin's 
lymphoma. J Clin Oncol 2012 Jun;30(18):2183-9.  
122
 Yue Ma, Lydia Visser, Tjasso Blokzijl, Geert Harms, Çig carondem 
Atayar, Sibrand Poppema and Anke van den Berg The CD4+CD26− 
T-cell population in classical Hodgkin's lymphoma displays a 
distinctive regulatory T-cell profile Laboratory Investigation 2008;88: 
482–490  
Zhang T, Moh MC, Lee LH, Shen S.  The immunoglobulin-like cell 
adhesion molecule hepaCAM is cleaved in the human breast 
carcinoma MCF7 cells. Int J Oncol 2010 Jul;37(1):155-65. 
 
Zhaorigetu S, Yanaka N, Sasaki M, Watanabe H, Kato N. Silk protein, 
sericin, suppresses DMBA-TPA-induced mouse skin tumorigenesis 
by reducing oxidative stress, inflammatory responses and 
endogenous tumor promoter TNF-alpha. Oncol Rep 2003 May-
Jun;10(3):537-43. 
 
 
123
